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The cell is governed by the complex interactions among various types of biomolecules.
Coupled with environmental factors, variations in DNA can cause alterations in normal
gene function and lead to a disease condition. Often, such disease phenotypes involve
coordinated dysregulation of multiple genes that implicate inter-connected pathways.
Towards a better understanding and characterization of mechanisms underlying human
diseases, here, I present GUILD, a network-based disease-gene prioritization frame-
work. GUILD associates genes with diseases using the global topology of the protein-
protein interaction network and an initial set of genes known to be implicated in the
disease. Furthermore, I investigate the mechanistic relationships between disease-genes
and explain the robustness emerging from these relationships. I also introduce GUILD-
ify, an online and user-friendly tool which prioritizes genes for their association to any
user-provided phenotype. Finally, I describe current state-of-the-art systems-biology
approaches where network modeling has helped extending our view on diseases such as
cancer.
Resum
La cèl·lula es regeix per interaccions complexes entre diferents tipus de biomolècules.
Juntament amb factors ambientals, variacions en el DNA poden causar alteracions en la
funció normal dels gens i provocar malalties. Sovint, aquests fenotips de malaltia invo-
lucren una desregulació coordinada de múltiples gens implicats en vies interconnecta-
des. Per tal de comprendre i caracteritzar millor els mecanismes subjacents en malalties
humanes, en aquesta tesis presento el programa GUILD, una plataforma que prioritza
gens relacionats amb una malaltia en concret fent ús de la topologia de xarxe. A par-
tir d’un conjunt conegut de gens implicats en una malaltia, GUILD associa altres gens
amb la malaltia mitjançant la topologia global de la xarxa d’interaccions de proteı̈nes.
A més a més, analitzo les relacions mecanı́stiques entre gens associats a malalties i ex-
plico la robustesa es desprèn d’aquesta anàlisi. També presento GUILDify, un servidor
web de fácil ús per la priorització de gens i la seva associació a un determinat fenotip.
Finalment, descric els mètodes més recents en què el model·latge de xarxes ha ajudat a




Science and technology have been continuously pushing the limits of our under-
standing of our habitat and our lives. Not only they change the way we perceive the
universe but undoubtedly they also redefine how we “survive” in it. Consequently, we
inform, express, entertain or even nurture ourselves in different ways than we used to
do1.
Rather ironically, science itself has taken its share from the change. Multi-disciplinary
fields (such as computational biology) have emerged and large scale experimental and
computational techniques have become increasingly available. Due to the accumulative
nature of science, often one may feel that the problem he/she tries to address is a highly
specific one, as opposed to key inventions we have witnessed over the past centuries.
Furthermore, there are many more researchers, articles and journals today then there
has ever been, making the criteria for the evaluation of the global impact of the research
conducted harder to set than it was done before2.
I can not say that I was fully aware of what was expecting me when I decided to
embark a carrier on computational biology research several years ago, after I graduated
from the university with a degree in computer engineering. Biology has always attracted
me and I thought it was a brilliant idea to combine informatics with biology when I first
heard about bioinformatics. Then, all of a sudden, I found myself in the middle of a
huge jungle, the jungle of computational biology. The boat I have taken on the river
passing through this jungle brought me to the laboratory of Baldo Oliva, where the
preliminary ideas of this thesis was born on the top of recent findings suggesting that
the genes encoding proteins that interact with each other tend to share similar functions
or tend to be involved in similar diseases. There started another journey within the
journey. Though initially was a “small-scale” project, developing algorithms to assess
the relatedness of genes within the context of protein-protein interaction network and its
implications on the characterization of diseases ended up being the main commitment
of this thesis.
During the fruitful years of graduate studies, at least I have learnt one thing for sure:
as long as you do something you like to do and you spend enough effort to rational-
ize the concepts you are working on, failure is not an option. And this is probably the
most important thing I have learnt. Another lesson I have taken home with me is that
Parkinson’s law3 also applies in the case of scientific works. That is, apart from pro-
crastination, new questions to be addressed are added into the project, to fill the time
allocated for the project.
All in all, it has been a great pleasure to have worked on a subject that I was inter-
ested in and I am glad that I have the opportunity to report what I have done during the
past four or so years in this thesis. I hope you find it handy.
1Though, these changes are often coined with the word “improvement”, –taking into account the
overall effect they cause on the (dis)order in the nature– I argue that there are actually few cases where
the world has unambiguously became a better place for everyone.
2Still, “thanks” to the overwhelming consumption capacity of mankind, relatively small scientific
and technological innovations such as the ones in the fields of hardware development, search engine
optimization, online marketing and social networks have had a huge impact on our daily lives.
3Proposed by Cyril Northcote Parkinson in 1955, Parkinson’s law reads as follows: work expands to
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No two humans, including monozygotic twins, are genetically identical. The reason
for this is the variation in genetic sequence (i.e. mutations during development in the
case of monozygotic twins). Although such variations flourish genetic diversity, not all
of them are beneficial for the organism. Some mutations, in combination with envi-
ronmental factors, can disrupt the complex machinery of the cell and cause functional
abnormalities. The past decade has witnessed dramatic advances in genome sequencing
and a substantial shift in the number of genetic association studies, therefore strength-
ening our understanding behind disease phenotypes. Nevertheless, the genetic elements
and mechanisms underlying diseases are still not very well characterized. Pathopheno-
typic characterization remains as a complex problem, mostly due to the pathophenotype
being the outcome of the perturbations in the inter-connected pathways, where products
of typically more than one gene co-operate through various mechanisms.
This thesis aims to extend our understanding of disease phenotypes incorporating
information encoded in the protein-protein interaction network. In this chapter, I will
briefly go over basic concepts related to the subject. In the following chapter, I will
introduce a network-based phenotypic characterization method and demonstrate that
it outperforms similar methods using protein-protein interactions (PPIs) when applied
to the problem of disease-gene prioritization in human. Then, I will investigate the
behaviour of the network-based prioritization methods against random perturbations
and show that for several diseases, disease-gene annotations are easier to be recovered
with network-based prioritization methods even when as much as half of the interaction
network is perturbed. Next, I will present a web-server version of the prioritization
method that can be run by entering only some keywords defining the phenotype. In
the last chapter, I will explain how protein-protein interaction networks have helped
understanding cancer progression. Finally, I will conclude with a discussion of the
findings presented in this thesis.
1.1 From genotype to phenotype
Genotype of the organism gives rise to the phenotype. Genotype is the inheritable infor-
mation coded within the organism. Phenotype is the physical manifestation –anything
that is part of the observable structure, function or behavior– of a living organism.
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In genetics, allele is one of the possible forms of a gene (or a genetic locus). Hu-
mans, like most multicellular organisms are diploid which means that there are two sets
of chromosomes in human somatic cells. In each of these chromosomes resides one
allele (a copy of each gene). If the same, the two alleles (in the two chromosomes) are
homozygotes, if different they are heterozygotes. Individuals of a population typically
have multiple alleles at each locus in their chromosomes yielding in different observ-
able phenotypes (polymorphism). For example, blood type in humans is a three-allele
phenotype (A, B, 0) where the alleles in two chromosomes in one individual defines the
three phenotype (A, B, 0) through one of the six possible genotypes (AA, A0, BB, B0,
AB, 00).
Predicting the phenotype of an organism (or the phenotype of the cells taken from it)
is a complex problem. To begin with, our knowledge on the genetic elements mediating
the phenotype is fairly limited. Furthermore, due to synergistic nature of genes involved
in biological processes, the same mutation may even lead to different phenotypes for
phenotypically identical individuals of the same organism given two different genetic
backgrounds [Dowell et al., 2010]. Yet, understanding the variations in DNA sequence
is the first step towards characterizing phenotypes, in particular disease phenotypes.
1.1.1 Variations in human genome
Depending on their frequency of occurrence in the population, human genetic variants
can be either common or rare. Common variants, are the genetic variants where the
minor allele (less common allele) frequency (MAF) is 1% or higher in the population.
Rare variants, on the other hand, have a MAF of less than 1%. Polymorphisms are
considered as common variants rather than rare variants since they are mediated by
inheritance and thus their prevalence in the population is higher (equal or higher than
1%) than one would expect as a result of random mutations.
Alternatively, the human genetic variations can also be grouped in two main cate-
gories with respect to the change in the nucleotide composition they incur (Figure 1.1).
Figure 1.1: Examples of genetic variation in human (reproduced from [Frazer et al.,
2009])
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Single nucleotide variants Single nucleotide variants consist of single point mutations,
that is alteration of a single nucleotide (A,T,G or C) in the DNA sequence. Single
nucleotide substitution, also known as single nucleotide polymorphism (SNP), are
among the most common human genetic variants. The human genome consists
of 3 billion nucleotide base pairs and it is estimated to contain at least 11 million
SNPs, all occurring with a MAF of over 1% and some 7 million of them occurring
with a MAF of over 5% [Frazer et al., 2009]. Nonetheless, most of the SNPs are
neutral (has no effect on the phenotype) and only a small portion of SNPs (around
5%) are functional. The alleles of SNPs located in the close genomic intervals
tend to be inherited together yielding in linkage disequilibrium (non-random as-
sociation of alleles).
Structural variants All DNA sequence differences between variations individuals of a
population, that are not single nucleotide variants are broadly defined as structural
variants. Typically, these variants affect a sequence length of 1kb (=kilo base) to
3Mb (=mega base). Structural variants are estimated to account for more than
20% of all genetic variants in humans covering more than 70% of the variant
bases [Frazer et al., 2009]. Structural variants are mainly categorized as follows:
• Copy number variation (CNV): A segment of DNA that is present at differ-
ent number of copies in comparison to a reference genome. CNVs occur due
to large (>1kb) insertions, deletions or duplications in the DNA sequence.
CNVs are estimated to account for roughly 13% of human genomic DNA
[Stankiewicz and Lupski, 2010].
• Insertion-deletion (indels): Insertion or deletion of several (less than 1kb)
nucleotides.
• Inversion of DNA sequence: A segment of DNA that is reversed in orienta-
tion with respect to the rest of the chromosome.
• Translocation: A change in position of a chromosomal segment within a
genome. Translocations do not change the total DNA content.
It is worth mentioning that other schemes for the classification of genetic variations
exist. These include classification by effect on function (loss- or gain-of-function muta-
tions), by effect on fitness (harmful, beneficial or neutral mutations), by contribution to
the phenotypic variation (neutral, near-neutral or non-neutral) or by impact on protein
sequence (frameshift, nonsense, missense, neutral or silent mutations).
A wide variety of methods has been developed to detect human genetic variations
experimentally [Feuk et al., 2006]. These methods can be broadly categorized with
respect to their coverage: genome-wide scans (covering all the DNA sequence) and
targeted scans (directed to a certain subsection of the DNA sequence). See Table 1.1 for
an overview of the experimental methods used to identify human genetic variants.
1.1.2 Human genetic variants and diseases
Most human diseases are complex genetic traits that are influenced by multiple genetic
and environmental factors. During the past decades, a substantial amount of effort has
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Table 1.1: Methods for detecting human genetic variants (adapted from [Feuk et al., 2006])*.
Method Small sequence CNV Translocation










s Karyotyping No Yes (>3 Mb) Yes (>3 Mb)
Clone-based array-CGH No Yes (>50 kb) No
Oligonucleotide-based array-CGH No Yes (>35 kb) No
SNP array Yes (SNPs) Yes No
Sequence-assembly comparison Yes Yes Yes








Microsatellite genotyping Yes Yes (deletions) No
MAPH Yes Yes No
MLPA Yes Yes No
QMPSF Yes Yes No
Real-time qPCR Yes Yes No
FISH No Yes Yes
Southern blotting Yes Yes Yes
* CGH, comparative genome hybridization; FISH, fluorescence in situ hybridization (including
metaphase, interphase and fibre); MAPH, multiplex amplifiable probe hybridization; MLPA,
multiplex ligation-dependent probe amplification; QMPSF, quantitative multiplex PCR of
short fluorescent fragments; qPCR, quantitative PCR
** >8 kb of deletions; <40 kb of insertions
been exerted to delineate sequential variations in human DNA and their consequences
on human biology [Altshuler et al., 2008]. These studies have established ties between
genetic variations and diseases in human where the genetic variant contributes to the
susceptibility for a diverse set of diseases. For example, a number of SNPs are known
to affect susceptibility to many Mendelian and complex diseases including cancers,
diabetes, asthma, obesity, schizophrenia, Parkinson disease, Alzheimer’s Disease (see
[Shastry, 2002, Hirschhorn et al., 2002] for two reviews on the topic). Furthermore, in-
versions in DNA have been identified to be involved in haemophilia, Hunter syndrome
and muscular dystrophy [Feuk et al., 2006]. Copy number variations have also been
found to be associated with different types of cancer, Crohn’s disease, Alzheimer’s Dis-
ease and neuropsychiatric conditions such as autism, schizophrenia [Stankiewicz and
Lupski, 2010, Eichler et al., 2007, Jr and Scherer, 2008].
Recombination mapping is among the earliest methods to identify disease causing
genes and mutations. Also known as linkage analysis, recombination mapping consists
of genotyping the alleles of individuals within a family at particular genomic poly-
morphic loci (sites on each chromosome) and then checking whether a certain variant
shows correlated segregation with a particular trait or disease. The genomic vicinity
of the identified chromosome region is typically further genotyped (e.g., by positional
cloning) to identify the exact casual locus for the trait or disease. The experimental
design has an important role in defining the effectiveness of recombination mapping.
In particular, i) the phenotype under consideration should be clearly definable (as op-
posed to intermediate phenotypes), ii) the phenotype should bear obvious genetic basis
(i.e. supporting evidence from studies on twins) and iii) the population should be se-
lected such that the genetic homogeneity is maximized and environmental factors are
minimized (e.g., isolated populations) [Broeckel and Schork, 2004].
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Recombination mapping has been used to identify genetic factors contributing sig-
nificantly to several Mendelian or monogenic diseases such as cystic fibrosis and Hunt-
ington’s disease and neurofibromatosis [Broeckel and Schork, 2004, Carlson et al.,
2004]. However, its success in identifying casual genes in complex traits is shuttered
due to the polygenic nature of these phenotypes. Complex disease phenotypes involve
many genetic variants and contribution of a genetic variant to the phenotypes might be
confounded by other genetic variants. Association studies offer a promising alterna-
tive to detect casual loci in human diseases by comparing the frequencies of genetic
variants between affected and unaffected individuals [Hirschhorn et al., 2002]. Re-
cently, the advancement in the sequencing techniques gave rise to genome-wide asso-
ciation studies (GWAS) where the association between the disease group (individuals
bearing the phenotype) and the control group (healthy individuals) is investigated at
genome level [Hirschhorn and Daly, 2005] (see Figure 1.2 for the overview of a typi-
cal GWAS). GWAS have been reported numerous novel associations for a wide range
of common diseases and clinical conditions such as age-related macular degeneration,
diabetes, obesity, inflammatory bowel disease, prostate cancer, breast cancer, colorec-
tal cancer, rheumatoid arthritis, systemic lupus erythematosus, celiac disease, multiple
sclerosis, glaucoma, gallstones, asthma, coronary heart disease, atrial fibrillation and
restless leg syndrome as well as continuous traits such as lipid levels, height, fat mass,
hair color, eye color, freckles and HIV viral set point [Altshuler et al., 2008, McCarthy
et al., 2008].
Genetic association studies pose intrinsic limitations affecting the interpretation and
applicability of the findings from these studies [Hirschhorn et al., 2002, Wang et al.,
2005, Hirschhorn and Daly, 2005, Frazer et al., 2009]. Probably one of the most strik-
ing concerns attributed to genetic association studies is the dependence on the sample
population and thus reproducibility. Sample size also plays as an important factor in the
reliability of the outcome of the study. Furthermore, these studies often fail to identify
rare high risk variants and modest risk variants with small effect sizes for which the
contribution to the disease prevalence is more than rare high risk variants. The analysis
of the findings is further complicated by the fact that a large portion of the identified
loci does not correspond to part of the DNA that is transcribed. Even for the sequence
variants that correspond to genes, most of these variants do not induce a change in the
protein sequence. Such changes are predicted to rather have implications on the tran-
scriptional or translational efficiency and on the gene expression [Hardy and Singleton,
2009, Frazer et al., 2009]. Additionally, so far, the association studies have not been
able to take the effects of gene-gene and gene-environment interactions into account.
Consequently, for most of the disease-gene associations annotated using genetic associ-
ation studies explain much less than 10% of the genetic variance [Frazer et al., 2009].
Therefore, improved experimental design strategies and more comprehensive functional
annotation methods have taken priority in the research community in order to explain
the links between genomic intervals and complex traits [Freedman et al., 2011, Clarke
et al., 2011].
1.1.3 Disease-gene association databases
The major data sources providing information on human genetic variants are given in
Table 1.2. Among these, Online Mendelian Inheritance in Man (OMIM) [Amberger
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Figure 1.2: Overview of a genome-wide association study (GWAS) (taken from
[Kingsmore et al., 2008])
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et al., 2009], SwissVar [Mottaz et al., 2010], Human Gene Mutation Database (HGMD)
[Stenson et al., 2009] and Genetic Association Database (GAD) [Becker et al., 2004] an-
notate the genetic variants and genes associated with the human disorders and diseases.
These databases are primary source of curated disease-gene annotations reporting asso-
ciations identified by experimental studies.
In particular, most studies rely on the data in OMIM [Amberger et al., 2009] since
it is one of the most comprehensive, authoritative and up-to-date repositories on human
genes and genetic disorders. The information in OMIM is expert curated and lists a
reviewed overview of the mutations associated with the diseases along with the publica-
tions reported them. Phenotypic associations for genes can be downloaded from OMIM
morbid map (omim.org/downloads), a file containing entries in the following for-
mat: disorder name, disorder MIM id (MIM is a six digit number describing phenotypes
and genes in OMIM), known genes whose mutations are associated with the phenotype,
MIM id of the gene whose association is biologically and historically most significant
and the associated linkage interval. Similarly, GAD [Becker et al., 2004] provides valu-
able information on disease-gene associations cataloging disease-gene associations cu-
rated from genetic association studies. GAD collects findings of low significance in
addition to those with high significance.
Several pharmacogenomic projects such as PharmaKGB [Hernandez-Boussard et al.,
2007], The Comparative Toxicogenomics Database (CTD) [Davis et al., 2010] and Ky-
oto Encyclopedia of Genes and Genomes (KEGG) [Kanehisa et al., 2012] compile in-
formation on disease-gene associations as well. Furthermore, computationally derived
“meta databases” such as GeneCards [Safran et al., 2010], PhenoGO [Sam et al., 2009],
PhenomicDB [Groth et al., 2007] and DisGeNet [Bauer-Mehren et al., 2010] integrate
data from mutliple data resources. In addition to these sources, a number of large-scale
projects sequencing various types of cancer catalogs somatic mutations in oncogenesis
(see cancer genes and variants part in the Table 1.2).
1.1.4 Disease-gene prioritization
Experimental studies provide valuable sources of information on the genetic variants
and the associated disorders, however often these studies identify a large genomic in-
terval containing as many as thousands of genes. Pinpointing the casual disease-gene
requires further experimental testing which increases the costs associated with identify-
ing disease-genes substantially. During the past decade, numerous computational meth-
ods have been developed to find the most promising candidates among a list of possible
genes. Named as disease-gene prediction/prioritization methods, these methods em-
ploy “guilt-by-association” principle. That is, the genes linked to known disease-genes
somehow will be more likely to be implicated in a disease. Disease-gene prioritization
methods narrow down the list of the candidates using various types of evidences are
given below (Table 1.3). Different types of evidences used to associate genes with each
other are described below (see [Kann, 2010, Tranchevent et al., 2011, Capriotti et al.,
2012] for three extensive reviews).
Sequence / structure Common sequence and structural similarity give rise to homol-
ogy and thus functional similarity. Disease phenotypes are more likely to in-
volve genes with similar function, thus similarity at sequence and structural level
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Table 1.2: Available data repositories for genetic variants and disease-gene associations


















NHGRI GWAS Catalog www.genome.gov/gwastudies
Cancer genes and variants
ICGC www.icgc.org
COSMIC sanger.ac.uk/genetics/CGP/cosmic
Cancer Gene Census sanger.ac.uk/genetics/CGP/Census
Cancer Gene Index ncicb.nci.nih.gov/NCICB/projects/cgdcp
TCGA cancergenome.nih.gov















implies involvement in similar disease phenotypes. In particular, disease-genes
could be distinguished from non-disease genes by their coding region length, se-
quence conservation, exon number, structural domains, sequence motifs, chromo-
somal location, (proteins’) subcellular location.
Pathway involvement Disease genes affect various biological pathways consisting of
genes that are interconnected with each other. The genes in the same pathway
perform similar functions, therefore, genes pertained in a pathway implicated in a
disease have an increased likelihood of being disease-related. In addition to path-
ways annotated in the literature (such as KEGG [Kanehisa et al., 2012], Reactome
[Croft et al., 2011], BioCyc [Caspi et al., 2011], GenMAPP [Salomonis et al.,
2007] and MSigDB [Liberzon et al., 2011]), regulatory networks (e.g., functional
links such as gene co-expression) and PPI networks are widely used to define the
biological context of the genes [Barabasi and Oltvai, 2004].
Non-human data Transferring functional information from non-human species (or-
thology) can shed light on disease-genes in human.
Ontologies Common ontological annotation (e.g., from GO [Ashburner et al., 2000])
provides clues on functional and phenotypic similarity making it possible to as-
sociate genes with diseases.
Literature Extracting disease-gene relationships through (text-)mining the literature
can also reveal links between genes and diseases (e.g., by checking co-occurrence
of relevant terms).
Mutations Several methods use existing knowledge / predictions on functional and
structural effects of the mutations. Note that, a related set of tools are available
for the functional annotation of SNPs. These tools are reviewed elsewhere [Kann,
2010, Karchin, 2009, Capriotti et al., 2012].
The evidence types explained above are used to describe “similarity” between known
disease-genes and candidate genes in the guilt-by-association scheme, such that if a gene
is similar to known disease-genes, it is also predicted to be implicated in the pathology
of the disease. Over the past decade, the amount of pathway information (coordinated
gene-gene relationships) such as gene co-expression patterns and PPIs has accumulated
rapidly (e.g., high-throughput techniques to detect gene expression and interactions).
Considering this continuous growth in the information, among these different evidence
types, pathway involvement based approaches to describe the similarity have particu-
larly attracted interest for their unmatched potential in identifying novel associations.
The disease-gene prioritization methods using PPIs to describe similarity to genes
already known to be associated with a disease (seeds) can be distinguished by the way
they define proximity between the gene products in the network of PPIs. Early attempts
to identify novel disease genes check whether the protein encoded by the gene of in-
terest interacts with the products of seeds (direct neighborhood) [Xu and Li, 2006, Oti
et al., 2006, Lage et al., 2007, Pujana et al., 2007, Wu et al., 2008, Aragues et al., 2008].
Though the direct neighborhood (direct interaction partners) of genes offers substantial
benefits to describe similarity between genes, this approach can be extended indirect
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* (E) Experimental observation (S) Sequence, structure, tissue specificity (P) Pathway involvement
(N) Non-human data (O) Ontologies (M) Mutations (L) Literature
** Resource not available at the time of redaction
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connections between genes (e.g., neighbors of neighbors in the network). For this pur-
pose, several studies utilize clustering based methods [Milenkovic et al., 2010, Navlakha
and Kingsford, 2010]. More recently, in order to fully exploit the network topology,
global topology based approaches have been proposed. Some of these works rank the
genes in the network with respect to the shortest distance between disease genes [Franke
et al., 2006, Wu et al., 2008, Kohler et al., 2008, Dezso et al., 2009]. Some other works
use kernel based diffusion over the links of the network (where the furtner nodes have
less influence) [Ma et al., 2007, Nitsch et al., 2010, Qiu et al., 2010] while some oth-
ers simulate a random walk model (where each node is assigned with the probability
of a random surfer ending up in the node while surfing through the links of the net-
work) [Kohler et al., 2008, Chen et al., 2009, Vanunu et al., 2010]. Methods based in
global topology, especially the ones based on random walks were demonstrated to out-
perform methods based on local topology [Kohler et al., 2008, Navlakha and Kingsford,
2010, Vanunu et al., 2010]
Taking into account incompleteness (false negatives) and noisiness (false positives)
of available PPI data, statistical adjustment methods to remove the bias towards highly
connected known disease nodes in PPI networks has also been proposed [Erten et al.,
2011] where the scores computed by prioritization algorithms are normalized using ran-
dom networks. Furthermore, several approaches incorporate gene expression and data
on functional similarity in addition to physical PPIs [Franke et al., 2006, Aerts et al.,
2006, Aragues et al., 2008, Ala et al., 2008, Linghu et al., 2009] to increase the quality
of the network underlying the methods mentioned above.
1.2 Systems biology
The cell is governed by the complex interactions of various types of biomolecules such
as DNA, RNA, proteins and small molecules. With the recent advances in biological
data collection and bioinformatics techniques, the gene-centric approaches for pheno-
typic characterization are being replaced by more systematic approaches that account
for the interactions between biomolecules. In order to characterize the dynamics of
the biological system, systems biolgoy studies interactions between the components of
biological systems within the framework of the biological system as a whole.
Through integration of different data sources such as protein sequence, gene expres-
sion and protein-protein interactions, our understanding on the functioning of the organ-
ism has evolved rapidly towards the co-operation of groups of biomolecules that con-
stitute biological networks including metabolic networks, PPI networks, regulatory net-
works (i.e. gene-protein interactions) and genetic interaction networks (i.e. gene-gene
interactions). Furthermore, these networks are interconnected with the biomolecules
shared between each other.
Network biology is the study of these coupled biological networks giving rise to
the behaviour of the cell. It aims to “map out, understand and model in quantifiable
terms the topological and dynamic properties of the biological networks” [Barabasi and
Oltvai, 2004]. Considering that the diseases arise from perturbations in the biological
networks underlying the cellular processes, network biology plays a key role in provid-
ing insights to disease mechanisms.
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1.2.1 Protein-protein interaction (PPI) networks
The proteins encoded by the genotype of the organism determines the observed pheno-
type (e.g., proteins giving the color of the eye). Although the components involved in
the translation from the genetic trait to the phenotypic outcome remain elusive engaging
all types of biological networks mentioned above, the interactions between proteins are
among the most important.
A variety of experimental techniques has been developed to detect whether a pro-
tein interacts with other proteins. These techniques are given in Table 1.4 along with
method-specific information such as the ability to detect binary interactions and/or com-
plexes, the applicability at large scale and the capacity to provide structural information.
Table 1.4: PPI detection methods (adapted from [Garcia-Garcia et al., 2012])
Method Binary Complex High-throughput Structure
Yeast Two Hybrid (Y2H) X X
Mammalian PPI trap (MAPPIT) X
Tox-r dimerization assay (TOXCAT) X
Bimolecular Fluorescence
Complementation (BiFC) X






Energy Transfer (BRET) X
Protein microarrays X X X
Surface Plasmon Resonance
Array (SPR) X X
Tandem Affinity Purification (TAP) X X
Cryo-electron microscopy X X X
X-ray crystallography X X X
Nuclear Magnetic Resonance (NMR) X X X
The PPIs identified using experimental techniques are deposited in various databases
such as BIND [Isserlin et al., 2011], BioGRID [Stark et al., 2010], DIP [Salwinski
et al., 2004], HPRD [Keshava Prasad et al., 2009], IntAct [Kerrien et al., 2011], MINT
[Licata et al., 2011], MIPS [Mewes et al., 2010], and MPact [Guldener et al., 2006]. In
order to compile interaction data spread in such databases, several computational tools
including PIANA [Aragues et al., 2006], ONDEX [Kohler et al., 2006] and BIANA
[Garcia-Garcia et al., 2010] have recently been developed. Yet, due to the interaction
data not being complete (false negatives), containing noisy interactions (false positives)
and not being able to capture the time and location dependent aspects of the cellular
events, the networks created using available interaction data serve as a snapshot of the
PPI networks.
1.2.2 Understanding disease mechanisms through PPI networks
Aberrations in normal gene function lead to a disease condition. However, complex dis-
ease phenotypes rarely result from a single disease-gene. Thus, human genetic disorders
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often involve coordinated dysregulation of multiple genes that implicate interdependent
pathways. PPI network modeling comes into play in order to spot such disease-genes
engaged in interrelated biological processes.
The topological information encoded in the PPI network provides valuable insights
to complex diseases [Ideker and Sharan, 2008, Vidal et al., 2011]. For instance, re-
cent studies demonstrated that proteins encoded by disease-genes tend to interact with
each other compared to the rest of the proteins [Gandhi et al., 2006, Goh et al., 2007].
Under the light of these findings, exploiting aforementioned guilt-by-association princi-
ple, network-based disease-gene prioritization methods associate genes using the links
in-between genes such as the topology of the PPI network [Barabasi et al., 2011]. Fur-
thermore, methods using global topology of the network have been demonstrated to
outperform methods than methods taking only the local or no topology information into
account [Navlakha and Kingsford, 2010].
The benefits of network modeling can be further improved by integrating differ-
ent types of biological data. Among various types of key molecular information such
as data on post-translational, transcriptional (e.g., gene expression profiles), metabolic
and epigenetic events help to define a finer-grained biological context. Consequently,
towards characterizing disease states, several studies have overlaid gene-expression pat-
terns over the PPI network and identified groups of genes that account for the dysregula-
tion observed in various cancer types (active subnetworks) [Nibbe et al., 2010a]. These
subnetworks were also shown to mediate the survival patterns and distinguish between
good and poor prognosis patient groups better than conventional (single gene-based)
biomarkers [Chuang et al., 2007].
1.2.3 Robustness as an emergent property of biological networks
Complex systems are intrinsically tolerant to internal mechanistic failures and changes
in environmental conditions. Biological organisms are not an exception [Kitano, 2004].
In biological systems, robustness is mainly achieved by controlling the system through
feedback [Morohashi et al., 2002], decoupling the parts of the system as functional
modules [Hartwell et al., 1999] and redundancy [Agrawal, 2001].
Network topology has an important role in generating robustness [Albert et al., 2000,
Barabasi and Oltvai, 2004]. Particularly, PPI networks are shown to be scale-free, that
is the degree distribution follows a inverse power law (P (k)∼k−γ where k is the degree
of a node and 2 < γ < 3). The scale-free property of PPI networks implies that most of
the proteins in the network have few connections and there are only a small number of
hub proteins that connect a large number of proteins [Barabasi and Oltvai, 2004]. Scale-
free networks bear so called “ultra small world” property such that the paths connecting
nodes are much shorter than what would be expected in a random network [Barabasi
and Albert, 1999]. Moreover, PPI networks have a high clustering coefficient, bringing
genes together in relatively more densely connected modules.
Though groups of genes in a cell are organized to minimize the effects of perturba-
tions, biological systems are prone to be disrupted by certain types of rare but special-
ized perturbations leveraging the fragility of the system [Carlson and Doyle, 2002, Ki-
tano, 2004]. For example, seizing the hub proteins in PPI network can predominantly
break up the network [Albert et al., 2000].
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1.2.4 Cancer studies in the era of systems biology
Cancer is the disturbance of the regulation circuitry controlling normal cell growth
emerging from genetic and epigenetic perturbations mediated by environmental situ-
muli. A systems level understanding of the pathways underlying the progression of
cancer is key to delineate the mechanisms and counteract the consequences of cancer
(i.e. uncontrolled cell growth and invasion of other tissues) [Laubenbacher et al., 2009].
PPI networks provide a framework to study the functional relationships among the
biological molecules involved in cancer [Jonsson and Bates, 2006, Vogelstein and Kin-
zler, 2004]. However, PPI networks by themselves provide only a partial view of the
complex biological processes. A comprehensive understanding of cancer lies beneath
the integration of biological data at different levels such as genomic, transcriptomic,
proteomic and metabolomic and the analysis of the relationships between biomolecules
in a dynamic context [Hanahan and Weinberg, 2011]. For instance, complementary to
PPI networks, network models describing relationships between co-expressed genes can
capture the expression changes mediated by the disease [Ergun et al., 2007, Mani et al.,
2008].
Stem cell research has attracted substantial attention during the past years, due to
the regenerative capacity these cells bear. Embryonic stem cells (ESC) can produce
more stem cells (self-renewal) and can differentiate into diverse cell types (differenti-
ation potency). Studying the regulatory circuits governing ESC has provided insights
into mechanisms in several human diseases [Young, 2011], particularly in cancer [Ben-
Porath et al., 2008] where the tumor cell show a parallel proliferative and plastic be-
haviour to the one of the stem cell [Reya et al., 2001]. Furthermore, stem cells provide
precise disease models enabling valuable opportunities for drug discovery [Park et al.,
2008]. Though still at its infancy, stem cell based novel therapeutical applications are
also expected to drastically change the treatment of many diseases such as neurodegen-
erative disorders (e.g., through cellular replacement) [Lindvall et al., 2012]. ESC are
dynamically regulated by transcription factors and epigenetic modifiers such as miR-
NAs and methylation events [MacArthur et al., 2009]. Understanding the mechanisms
involved in the control of the stem cell behaviour and its relationship with the diseases
requires a system-wide modeling of the underlying network of the genetic and epige-
netic components.
1.3 Motivation of this thesis
The experimental data on the genetic variants and the disorders associated with these
variants shed light on our understanding of human genetic disorders as such data con-
tinue to accumulate. However, pinpointing genomic variants causing diseases is still
hindered by the expenses such experimental techniques incur. Computational tech-
niques such as network-based disease-gene prioritization methods play an indispens-
able role in the characterization and eventually prevention of the consequences of such
genomic variants on human health.
Typically, network-based approaches tackle the problem of prioritization of genes
within a linkage interval. Recently, these methods have also been applied to prioritize
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genes from GWAS [Lee et al., 2011, Akula et al., 2011]. In fact, using the whole
genome to prioritize disease-gene variants is expected to produce more robust results in
identifying modest-risk disease-gene variants than using high-risk alleles [Carlson et al.,
2004]. Nonetheless, existing prioritization methods substantially suffer from a lack of
linkage interval information [Navlakha and Kingsford, 2010] and depend on the quality
of the interaction network [Erten et al., 2011]. Furthermore, available network-based
prioritization methods treat all the paths between nodes equally relevant for a particular
disease.
Thus, network-based disease-gene prioritization can be improved. Such improve-
ment can then empower discovery of novel disease-genes and disease-related pathways








This thesis aims to fulfill the following objectives:
• To develop an algorithm that effectively exploits guilt-by-association principle to
transfer phenotypic annotation through the network topology.
• To evaluate the prediction of accuracy of the developed prioritization method (al-
gorithm) on human genetic diseases and compare it with existing methods.
• To assess the dependence of the developed prioritization method on the underly-
ing network and known disease-gene associations.
• To provide an online and user-friendly framework where the genes can be priori-
tized for their association to any user-provided phenotype.
• To investigate further uses of the developed method, particularly in complex dis-
eases such as cancer.
The first two objectives are addressed in the next chapter (Chapter 2) where I in-
troduce a network-based phenotypic characterization method and demonstrate that it
outperforms similar methods using protein-protein interactions (PPIs) when applied to
the problem of disease-gene prioritization in human. The dependence of the developed
prioritization method on the underlying network and known disease-gene associations is
investigated in Chapter 3. In accordance with the fourth objective, an online web-server
is presented in Chapter 4. The following chapter (Chapter 5), complies with the final
objective and provides an overview of network modeling approaches that have helped
understanding cancer progression.
In the appendix section, I include some of the works that I was involved during my
doctoral studies. These works are not directly related to the main objectives of the stud-
ies but are either used towards achieving or extending the goals of the thesis. BIANA,
a biological data integration tool, in the development of which I actively participated, is
introduced in Appendix A. BIANA compiles information on the biological molecules
and the relationships between them (such as PPIs) in a single database and provides an
easy way to access and analyze proteomics and interactomics data spread over various
databases. In Appendix B, a method to extend functional annotation of genes using PPIs
is described. In this work, starting from known elements of apoptosis signaling path-
way, PPIs are used to discover genes that are potentially involved in the same pathway.
I was involved in the implementation of network-based methods for functional exten-
sion and cross-validation analysis. I also contributed to a review on the acquisition,
integration, analysis and application of PPI information (Appendix C). Finally, in Ap-
pendix D, I present the results of an on-going collaboration with Trey Ideker’s group in
University California, San Diego in which I am responsible of analyzing genome-wide
gene-expression from various human cell samples at different points of differentiation
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Abstract
Complex biological systems usually pose a trade-off between robustness and fragility where a 
small  number  of  perturbations  can  substantially  disrupt  the  system.  In  genetic  diseases,  a 
mutation  perturbs  the  system  and  exploits  its  fragility.  Recent  advances  in  identifying  and 
analyzing the sequential  variations beneath human disorders help to comprehend a systemic 
view  of  the  mechanisms  underlying  various  disease  phenotypes.  In  this  study,  we  have 
hypothesized that disease-gene prioritization methods based on the network of protein-protein 
interactions can be employed to investigate the mechanistic relationships between disease-genes 
and explain the robustness emerging from these relationships.   Network-based disease-gene 
prioritization methods rank the relevance of genes in a disease under the hypothesis that genes 
whose proteins interact with each other tend to exhibit similar phenotypes. We have tested the 
robustness  of  several  network-based  disease-gene prioritization  methods  with  respect  to  the 
perturbations  of  the  system  using  various  disease  phenotypes  from  the  Online  Mendelian 
Inheritance in Man database. These perturbations have been introduced either in the protein-
protein interaction network or in the set of known disease-gene associations. As the network-
based  disease-gene  prioritization  methods  are  based  on  the  connectivity  between  known 
disease-genes,  we  have  further  used  these  methods  to  understand  the  plasticity  of  the 
pathophenotypes.  Our  results  have  suggested  that  pathophenotypes  such  as  breast  cancer, 




A fundamental characteristic of biological systems is tolerance to noise. The ability to counteract 
both internal mechanistic failures and changes in environmental conditions plays a central role in 
the survival of the organism.  The main components of robustness are controlling the system 
through negative and positive feedback (Morohashi et al., 2002), splitting the parts of the system 
as functional units (Hartwell et al., 1999) (modularity and decoupling), and phenotypic plasticity 
(Agrawal, 2001) (typically achieved by redundancy). In a biological system, groups of genes are 
optimized in functional decoupling, redundancy and diversity such that the effects of perturbations 
are minimized (H. Kitano, 2004a). However, complex biological systems have to balance between 
robustness and fragility which implies that a small number of rare perturbations can substantially 
disrupt the system (Carlson and Doyle, 2002). In particular, some mutations are the main cause 
of diseases by exploiting the fragility of the biological system. 
Similar to the underlying biological system, the disease phenotypes themselves are likely to be 
robust  against  external  changes (Pujol  et  al.,  2010). For  instance,  the robustness of  disease 
phenotypes has been recently discussed for HIV (H. Kitano, 2004a), diabetes (H. Kitano et al., 
2004) and cancer (H. Kitano, 2004b). Complex genetic disorders involve cooperation of multiple 
genes engaged in various biochemical pathways associated with a disease (Goh et al., 2007; 
Barrenas et al., 2009). Employing several genes often induces resilience against the mechanisms 
of  defense  of  the  organism.  Thus,  understanding  the  strengths  and  weaknesses  of 
pathophenotypes against perturbation can play a crucial role for developing effective therapeutic 
strategies (Pujol et al., 2010).
During the past decade, genome-wide efforts such as linkage analysis and association studies 
have successfully associated numerous causal loci with human disorders (Altshuler et al., 2008). 
Still,  much effort needs to be taken to fully understand the complex implications on the whole 
system and its  protein-protein  interaction  (PPI)  network.  Hence,  several  methods  have  been 
developed  to  amplify  available  disease-gene  associations  using  the  principle  of  “guilt-by-
association”.  These methods typically exploit  relationships of  the disease causing genes with 
other candidate genes, initially using the neighborhood of known associations in the physical (Oti 
et al., 2006; Xu and Li, 2006) or functional (Pujana et al., 2007) interaction network and more 
recently extending the approach to account for the global topology of the underlying network 
(Kohler et al., 2008; Chen et al., 2009). Although considering neighborhood to known disease 
causing genes is a simple approach to identify novel candidate genes, global topology based 
methods have proved useful in associating genes with the diseases they mediate (network-based 
disease gene prioritization) (Navlakha and Kingsford, 2010; Akula et al., 2011; Lee et al., 2011). 
Following the emergence of high-throughput experimental techniques that produce large amount 
of biological data, several studies have investigated robustness of a complex system in respect to 
the underlying network topology. Different types of networks have been studied with this purpose, 
such as metabolic networks (Jeong et al., 2000), protein-protein interaction networks (Jeong et 
al.,  2001;  Huang et  al.,  2006)  and regulatory  interaction networks  (Demongeot  et  al.,  2009). 
However, to our knowledge, robustness of network-based disease-gene prioritization methods, 
where the underlying network itself is perturbed, has not been extensively investigated. Due to 
the fact  that network-based disease-gene prioritization methods use the connectivity between 
genes associated with the disease, we hypothesize that they may serve to evaluate robustness of 
diseases against perturbations in the underlying interaction network. The definition of robustness 
is problem specific (Rizk et al., 2009). We define the robustness as the observed change in the 
prediction  capacity  of  the  prioritization  methods  when  perturbing  the  underlying  interaction 
network. 
In this paper, our main goal has been to test the quality and robustness of several network-based 
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disease-gene  prioritization  methods  against  perturbations  introduced  either  to  the  underlying 
protein-protein interaction network or to known disease-gene associations. Next, to investigate 
the relationship between robustness and modularity, we have examined the capability of these 
methods  to  identify  disease  modules  (groups  of  genes  that  are  enriched  with  the  functions 
relevant  to  the  disease).  We  have  used  these  results  to  decide  the  best  network-based 
prioritization approach.  Then, we have proven that  for some diseases,  the robustness of  the 
outcome of the network-based prioritization was a result of the connectivity of disease-associated 
genes in the underlying network. Therefore, through the analysis of the prediction performance of 
the  network-based  prioritization  method  under  in  silico perturbations,  we  have  categorized 
various disease phenotypes in Online Mendelian Inheritance in Man (OMIM) database (Hamosh 
et  al.,  2002)  with  respect  to  the pathophenotypic  plasticity.  Our results  have  suggested that 
several pathophenotypes, particularly the ones with high prevalence in the society such as breast 
cancer and diabetes, bore more plasticity than the rest of the compared pathophenotypes. We 
have found that  robustness of  the pathophenotype was independent  of  the number  of  initial 
genes associated with the disease and rather mediated by how well these genes are connected 
in  the  interaction  network.  Furthermore,  we  have  argued  that  robust  diseases  achieved 
pathophenotypic plasticity by pathologically aiming many more pathways compared to non-robust 
diseases.
Results and Discussion
Network-based  disease-gene  prioritization  methods  as  a  framework  to  investigate  biological  
robustness of pathophenotypes
Network-based disease gene prioritization methods rank the relevance of genes in a disease 
using  known  disease-gene  associations  and  the  network  topology.  Any  perturbation  in  the 
network topology induces a change on the ranking of  the genes for  the disease in concern. 
Systematically  introducing  perturbations  at  different  levels  and  analyzing  the  changes  in  the 
ranking of the disease-genes provide a way to measure the robustness of the prioritization. We 
hypothesize that if any, such robustness emerges either from the prioritization method applied or 
it  is  an intrinsic  characteristic  of  the pathophenotype in  concern.  Then,  if  we prove that  this 
robustness is not  due to  the method itself  but  caused by the connectivity  between the gene 
products of the genes associated with a disease, we can use this robustness as a measure of the 
plasticity of the pathophenotype. We adopt the plasticity concept for disease phenotypes following 
the original definition of phenotypic plasticity. Phenotypic plasticity is defined as the ability of a 
single  genotype  to  alternate  its  phenotype  in  response  to  environmental  conditions  (West-
Eberhard, 1989, -). Accordingly, we define phenotypic plasticity of a pathophenotype as its ability 
to  adapt  the  phenotype  in  response  to  changes  in  the  environment  while  preserving  its 
pathogenicity.  In  other  words,  pathophenotypic  plasticity  is  our  incapacity  to  affect  the 
pathophenotype with the use of drugs or chemical intervention (Hiroaki Kitano, 2007) and we 
model such possible interventions as perturbations introduced either in the interaction network or 
in the known disease-gene associations (seeds).  
To assess the tolerance of a given phenotype to the noise in the underlying interaction network or 
in the seeds, we used five network-based prioritization methods. The prioritization methods rank 
the nodes of the network according to their implication in the pathopheontype. The network-based 
prioritization approaches obtain this rank by disseminating the information of seeds through the 
protein interaction network. In this work, we applied recently proposed topology-based ranking 
algorithms available in GUILD software package (Guney and Oliva, 2011, [CSL STYLE ERROR: 
reference  with  no  printed  form.])  using  an  integrated  human  interactome  and  23  disease 
phenotypes curated from OMIM database (Hamosh et al., 2002). The human protein interaction 
network  was  obtained  by  extracting  human  protein-protein  interactions  from several  publicly 
available repositories and integrating them with BIANA (Garcia-Garcia et al., 2010). The network 
consists of 11250 nodes (gene products) and 59220 edges (physical interactions) connecting 
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them.  Initial  disease-gene  associations  were  retrieved  from  OMIM  (Hamosh  et  al.,  2002) 
database  for  phenotypes  that  have  at  least  25  causative  genes  associated  with  them (see 
Methods for details).  
First, we mapped the disease-gene associations to their corresponding nodes (these are named 
seeds) in the interaction network. Then, we introduced several perturbations on known disease 
gene associations and on the interaction network. Next, we used the network-based prioritization 
methods  on  the  original  and  perturbed  data  sets.  Finally,  we  evaluated  the  prediction 
performance of the prioritization methods (see methods for details). We compared the robustness 
of  five  prioritization  methods  at  different  percentages  of  perturbation  (see  next  section).  To 
explain the robustness, we compared the number of seeds, its location in the protein-interaction 
network  and  their  connectivity.  Interestingly,  we  proved  that  some  disorders  showed  higher 
robustness than others due to a different degree of connectivity between the seeds independent 
of the number of seeds. This argument was used to hypothesize that the degree of robustness 
could  also  rank  the  degree  of  resilience,  adaptation  and  plasticity  of  some  pathogenic 
phenotypes. Finally we categorized the disorders and analyzed them by means of the results of 
the disease-gene prioritization methods.
In silico analysis points out to alternative routes connecting the genes involved in disorders
We  first  questioned  whether  the  prioritization  methods  depend  on  the  number  of  genes 
associated with a disorder. To address the dependence on the number of seeds, we replaced the 
seeds  with  non-seeds  in  the  network  at  varying  percentages  (10%  to  100%).  That  is,  we 
disturbed  the  initial  disease-gene  associations  at  different  levels  by  introducing  wrong 
associations between genes and pathophenotypes.  Then we calculated the area under ROC 
curve (AUC) of network-based prioritization methods using a five-fold cross-validation setting on 
the  perturbed  disease-gene  annotations.  An  increased  percentage  of  mis-annotated  seeds 
reduced the reliability of predictions for all methods (Figure 1a). If more than 70% of seeds were 
false, the AUC reduced to less than 50% for all methods. Only NetShort resulted in an AUC 
higher than 50% with 40% false seeds. In conclusion, all methods were dependent on the quality 
of initial associations while NetShort was less affected, compared to the rest, in predicting new 
genes  associated  with  the  disease.  In  order  to  ensure  that  this  was  not  an  artifact  of  the 
interaction network, we repeated the analysis on the interaction network used by Goh et al. (Goh 
et al., 2007). This network contained a set of high confident protein-protein interactions in human 
(we refer to this network as Goh network hereafter, see Methods). The AUCs for the methods at 
different perturbation percentages using Goh network are given in Supplementary Figure 1a.
To prove the relevance of the quality of the interactions, we randomly swapped the edges of the 
network. Also, to investigate the relevance of the number of interactions, we randomly deleted 
edges of the network. The variation in the edges of the network ranged between 10% and 100%. 
We applied the prioritization methods to these perturbed networks and calculated the average 
AUC over all diseases. Figure 1b shows the decrease in AUC produced using false interactions 
(randomly swapped edges) for all methods. It is noteworthy that PageRank was the most robust 
method, the prediction performance of which was less affected from the perturbation of edges 
than the rest.  On the other hand, edge deletion decreased the AUC for NetScore, Functional 
Flow, and PageRank, but NetZcore and NetShort improved the prediction quality by increasing 
the AUC, and it only began to drop after more than 60% of the interactions were removed (Figure 
1c).  Repeating  the  same  analysis  with  the  Goh  network  revealed  that  the  prioritization 
approaches exhibit a similar behavior (Supplementary Figures 1b and 1c), indicating that these 
features were independent of the underlying network. Although this behavior was unexpected, it 
could be explained by the way the prioritization algorithms work.  These algorithms used the seed 
nodes to disseminate information through the network. For each disease, there were very few 
number of seeds compared to non-seeds in the interaction network. Therefore, random deletion 
of edges disconnected fewer seeds because the number of edges connecting two seeds was 
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much less than the number of remaining edges (that connected a seed and a non-seed or two 
non-seeds).  Consequently,  Functional  Flow  and  NetScore  were  more  affected  than  others 
because of their dependence on the number of paths that connected seeds with each other. 
However, the effect of deletion diminished in the case of NetZcore since it normalized the score 
using  random  networks  and  the  scores  of  the  nodes  connected  with  seeds  improved.  To 
understand this with an example, let’s take a node n that is relatively more connected to seeds in 
comparison to any of the random networks. The random deletion of an edge would be more likely 
to remove a link connecting a non-seed. Hence, it would be more likely that node n would remain 
relatively more connected to seeds in comparison to random networks.  NetShort, which used the 
shortest paths leading to seeds, also improved the quality of the predictions, probably due to 
seeds  having  secondary  routes  unaffected  by  the  deletion  of  links.  Such  backup  circuits 
constitute a fail-safe mechanism and explain the resilient nature of cells (H. Kitano, 2004a). 
The effect of perturbing interactions on the pathophenotype: the case of Alzheimer’s Disease
In Figure 1 we observed that the perturbations in the interaction network improved the prediction 
performance of several prioritization algorithms. In order to gain an insight on the consequences 
of  the  changes  in  the  interaction  network,  we  analyzed  the  connectedness  of  the  genes 
associated with the Alzheimer’s Disease (AD), a relatively well studied pathophenotype. We used 
the human interaction network and genes associated with AD in OMIM (Hamosh et al., 2002) 
(AD-seeds). We took the neighbors of seeds in the interaction network and checked how many of 
their neighbors are implicated in AD using an independent set of genes taken from literature 
(validation set, AD-related genes) (Krauthammer et al., 2004). We repeated this procedure on 
perturbed networks, interactions of which were either randomly swapped (permuted) or deleted 
(pruned) at different percentages (see Methods). Figure 2 shows the total number of genes and 
AD-related  genes  in  the  neighborhood  of  seeds.  Not  surprisingly,  as  the  percentage  of 
perturbation  increases,  the  number  of  AD-related  genes  in  the  neighborhood  of  AD-seeds 
decreased. However, in the case of interaction pruning, the ratio of AD-related genes versus the 
total  number of  genes in  the neighborhood of  AD-seeds increased. This  suggested that  AD-
related genes tended to remain connected with at least one AD-seed in the interaction network. 
Categorizing pathophenotypic robustness
The analysis of the prediction performance implied that disease-gene associations could still be 
recovered  considerably  using  network-based  prioritization  methods  even  when  half  of  the 
interactions were perturbed (see Figures 1b and 1c). We further investigated whether this was an 
intrinsic property of the disease. We first defined the robustness of a disease as the amount of 
perturbations  required  to  cause  a  “critical”  AUC  change  when  we  applied  network-based 
prioritization  to  predict  its  associated  genes  (see  Methods  for  details).  Among  the  different 
approaches to prioritize candidate genes we used NetScore for this analysis, since it had good 
overall prediction accuracy (Figure 1) and produced the smallest number of clusters coherently 
enriched in the functions related to the corresponding disease (see Supplementary Results and 
Supplementary  Figure  2).  Note  that  NetZcore  had  also  similar  properties,  however  the 
perturbation analysis above proved that NetZcore was robust against perturbations whereas the 
AUC for NetScore fell down linearly as the percentage of perturbations increased (Figure 1). In 
order to minimize the bias on the prediction performance due to using a robust  prioritization 
method and focus on the robustness of the disease, we selected NetScore over NetZcore. Thus, 
we  grouped  diseases  into  two  categories  based  on  the  differences  of  the  prioritization 
performance (assessed by the AUC) between the original network and perturbed networks using 
NetScore.  For  each pathophenotype,  we checked the amount  of  perturbation (both  for  edge 
swapping  and  removal)  required  in  the  interaction  network  that  caused  the  prioritization 
performance fall below the critical AUC. If after perturbing more than 50% of the interactions, the 
prioritization of a disease still achieved a performance higher than the critical AUC, we labeled 
this  disease  as  being  robust.  On  the  other  hand,  if  the  critical  AUC  was  reached  with 
63
perturbations affecting less than 50% of the interactions in the network, we labeled the disease as 
being non-robust. See Supplementary Figure 3 for the changes in the NetScore prioritization AUC 
upon perturbations in the interaction network for robust diseases. According to our criteria, robust 
pathophenotypes such as  breast  cancer,  cardiomyopathy,  diabetes,  insulin,  leukemia,  obesity 
and parkinson disease had larger plasticity and capability of adaptation against perturbations in 
the  underlying  network  than  the  rest  of  the  pathophenotypes.  It  is  worth  mentioning  that 
pathophenotypes with more plasticity or resiliency corresponded to diseases of high prevalence 
in developed countries.
Comparison between robust and non-robust pathophenotypes
We further checked whether the diseases in different categories bore similar properties in terms 
of  known disease  annotations  associated  with  disease  (seeds),  connectivity  of  these  seeds, 
modularity and functional plasticity. In principle one may think that the definition of robustness 
seems to be dependent on the number of seeds of the phenotype. This would also suggest an 
explanation  to  the  fact  that  diseases  of  high  prevalence  were  categorized  more  robust. 
Nevertheless, there was not a significant difference between the number of seeds of robust and 
non-robust  diseases  (Figure  3a).  In  contrast,  the  seeds  of  robust  pathophenotypes  were 
significantly connected to each other with shorter paths compared to non-robust pathophenotypes 
(Figure 3b, associated p-value with the two-sided Wilcoxon rank sum test was 0.03). This feature, 
the average length of shortest paths connecting any two seeds in a disease, was independent of 
the number of seeds. 
Next, to investigate the relationship between robustness and modularity, we have checked the 
number of modules associated with diseases (see Supplementary Methods and Supplementary 
Results).  Robust  diseases  showed  slightly  increased  modularity  compared  to  non-robust 
diseases (see the section on modules associated with diseases above) yet the difference in the 
number  of  clusters  grouping  similar  number  of  genes  in  both  categories  was  not  significant 
(Figure 3c).  Furthermore,  we counted the number of  GO terms enriched in the seeds of  the 
diseases (seed GO terms) for both categories. In order to avoid possible bias towards the number 
of seeds, we normalized the number of seed GO terms dividing them by the total number of 
seeds for  each pathophenotype.  Robust  diseases contained more seed GO terms per seed, 
proving that a larger number of biological functions associated with seeds were involved in robust 
diseases than in non-robust pathophenotypes (Figure 3d, associated p-value with the difference 
was 0.01). Similarly, the clusters of top ranked genes in robust diseases covered a larger number 
of seed GO terms than the clusters of non-robust diseases (Figure 3e). When we consider all GO 
terms enriched in the clusters, the clusters of robust pathophenotypes covered more GO terms 
than the clusters of non-robust pathophenotypes (Figure 3f). Although the difference between 
robust and non-robust pathophenotypes was only significant for the number of seed GO terms 
per seed, these findings suggested that robust phenotypes tended to group genes involved in a 
larger number of functions compared to non-robust phenotypes. Therefore, functional diversity 
might be more important for robustness than a particular biological function. We also calculated 
the Jaccard index for quantifying GO terms shared between each pair of diseases in the modules 
of  top  ranking  genes  (see  Supplementary  Figure  4).  Several  diseases  like  breast  cancer, 
lymphoma and ataxia had a large number of common functions compared to rest. Such common 
features at the functional level might be useful for understanding the etiology of complex genetic 
disorders (Cotterchio et al., 2002). Nonetheless, robust and non-robust pathophenotypes did not 
share a substantial amount of biological functions. 
Supplementary Figure 5 shows the GO terms shared by at least three diseases within robust and 
non-robust pathophenotypes. Robust pathophenotypes such as  leukemia, obesity and diabetes 
were observed to share GO terms of  biosynthetic  and metabolic  processes while  non-robust 
diseases shared GO terms associated with membrane activity. Remarkably, biological processes 
associated with regulation of cellular metabolism were more often implicated in robust diseases 
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than  in  non-robust  diseases,  which  supported  the  role  of  positive  and  negative  feedback 
mechanisms in defining robustness. 
Conclusions
In this study, we have analyzed robustness of several disease-gene prioritization algorithms that 
were based on known disease associations and protein-protein interaction networks. Our analysis 
on randomly perturbed interaction networks pointed to the existence of backup circuits within the 
interaction network constituting a fail-safe mechanism. Strikingly, the interactome might tolerate 
an interaction removal rate as high as 50%, the point at which methods using alternative paths 
start suffering from low prediction performance. This suggested that only half of the interactions of 
the network were sufficient to explain a given pathophenotype.  Our study has also shown the 
robustness  of  some  prioritization  methods  upon  perturbations.  NetZcore  and  NetShort  have 
shown to be consistently effective when reducing the number of interactions, while PageRank 
was instead more robust against the introduction of false interactions.
We  also  applied  the  prioritization  methods  to  identify  disease  modules  and  to  study  the 
implication of several biological processes in various diseases. Our findings confirmed that the 
prioritization methods were able to distinguish between groups of connected genes with functions 
identical to those of the known disease-associated genes (disease modules). 
We categorized diseases into robust and non-robust pathophenotypes using a network-based 
prioritization method.  Interestingly,  robust  pathophenotypes included many diseases with high 
prevalence  in  society.  We  further  investigated  whether  there  were  characteristic  differences 
between diseases involved in these categories. The connectedness of proteins encoded by seed 
genes (known disease-genes) stoke out as the most important factor in defining robustness of a 
pathphenotype. That is, a disease was more likely to be robust if the proteins encoded by the 
genes  involved  in  that  pathophenotype  were  connected  with  shorter  paths  to  each  other. 
Interestingly, our results suggest that network-based robustness of pathophenotypes may also be 
defined based on the connectivity of  seeds. We also observed that  genes involved in robust 
pathophenotypes were implicated in more biological  processes than the genes of  non-robust 
pathophenotypes.  The clusters of top prioritized genes in the robust pathophenotypes tended to 
be involved in a larger number of biological functions than the top ranking genes in the clusters of 
non-robust pathophenotypes.
Overall,  robust  diseases  bore  higher  connectedness  between  their  seeds  and  an  increased 
functional diversity, suggesting plasticity to some extend at pathophenotype level. The findings 
presented here may help developing novel network-medicine approaches that try to characterize 
the interconnected  pathways implicated in  diseases and possibly  suggest  points  of  action to 
compensate  these  changes  induced  by  the  disease  (Zanzoni,  2009).  Seed  connectivity  and 
functional diversity can explain why polypharmacological approaches, which typically target many 
gene products simultaneously via administration of  multiple drugs (Hopkins,  2008), may work 
better on some diseases such as AIDS or cancer (Yang et al., 2008; Vazquez, 2009; Motter, 
2010).
Methods
Gene–phenotype associations. Genes and their associated disorders were taken from Online 
Mendelian Inheritance in Man (OMIM) database (Hamosh et al., 2002). OMIM is one of the most 
comprehensive repositories of genes with Mendelian mutations and the disorders associated with 
them.  Phenotypic  associations  for  genes  were  extracted  from  the  OMIM  Morbid  Map 
(ftp://ftp.ncbi.nih.gov/repository/OMIM/morbidmap retrieved  August  27,  2009)  by  searching  for 
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keyword entries associated with the disorders given in  Supplementary Table 3. A disorder was 
considered if at least 25 genes were associated with it in the Morbid Map after merging several 
diseases  under  the  same  keyword  (e.g.,  for  Alzheimer’s  disease  we  collected  Alzheimer’s 
disease types 1, 2, etc... using the keyword “alzheimer”). Supplementary Table 3 summarizes all 
diseases used under the context of this study and the number of genes associated with them.
Genes associated with a disorder were mapped to their products (proteins) in the protein-protein 
interaction network and assigned an initial score for their phenotypic relevance. Thus, proteins 
translated by genes known to be involved in a particular pathology were termed seeds and have 
the highest score (1.0) in the network. All other proteins in the network were assigned a non-seed 
score (lowest score in the network: 0.01). The correspondence between genes and their products 
(proteins) was determined using the data integration protocol  of BIANA (Garcia-Garcia et  al., 
2010). 
Protein–protein  interaction  data  sets. We  compiled  a  human  protein-protein  interaction 
network from publicly available major interaction data repositories using BIANA integration tool 
(see  Supplementary  Table  4).  First,  protein-protein  interactions  from  different  sources  were 
integrated  with  BIANA  (Garcia-Garcia  et  al.,  2010)  to  obtain  a  human  interactome.  High 
throughput pull down interaction detection methods introduce many indirect relationships (such as 
being involved in the same complex) in addition to direct physical interactions. Thus, we removed 
the subset of interactions obtained by Tandem Affinity Purification (TAP) and called this network 
as  the bPPI (binary PPI) network.  We used the largest connected component of the network 
since we apply a set of methods based on the transfer of information through the edges of the 
network (i.e. unconnected nodes can not receive information from other nodes). This component 
will be referred as network hereafter. The disease-gene annotations from OMIM were mapped to 
the corresponding proteins in the network using gene symbols provided in UniProt database. 
Note that some of the gene-disease associations were excluded since not all gene products have 
an interaction in  the largest  connected component  of  human interactome.  We also used the 
human interactome from Goh et al. (Goh et al., 2007) (referred to as the Goh network), which 
combined two high quality yeast two-hybrid experiments (Rual et al., 2005; Stelzl et al., 2005) and 
PPIs obtained from the literature. 
Network-based prioritization of disease-genes. GUILD (Genes Underlying Inheritance Linked 
Disorders) is a network-based disease gene prioritization framework (Guney and Oliva, 2011, 
[CSL  STYLE  ERROR:  reference  with  no  printed  form.]). The  framework  contains  a  set  of 
methods which use known disease genes and their interactions to rank the relevance of genes in 
a disease or disorder based on the hypothesis that genes whose proteins interact with each other 
tend to exhibit similar features, such as function and/or phenotype. These methods require an 
initial  set  of  genes  associated  with  a  particular  phenotype  (e.g.,  a  Mendelian  disorder)  and 
interactions between the products of these genes. GUILD proposes three topology-based ranking 
algorithms:  NetShort,  NetZcore,  and  NetScore  (see  Supplementary  Methods  for  details). 
Additionally, two state-of-the-art algorithms have been included in GUILD: PageRank with priors 
(White and Smyth, 2003) (as used in ToppNet (Chen et al., 2009)) and Functional Flow (Nabieva 
et al., 2005). PageRank with priors has recently been proven to be superior to available topology-
based prioritization methods (Chen et al., 2009; Navlakha and Kingsford, 2010; Lee et al., 2011). 
We also apply Functional Flow, a method originally addressed functional annotation problem with 
success (Nabieva et al., 2005). 
Evaluation. To evaluate the prioritization methods, we used a five-fold cross validation. Proteins 
known to be associated with a phenotype (seeds) were split into five groups; four of them were 
used to apply the prioritization functions and one set to evaluate the prediction. This process was 
repeated  five  times,  changing  the  set  for  evaluation.  The AUC were  averaged  over  the  five 
evaluations. These averages and their standard deviations were used to assess the quality of the 
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predictions. ROCR package was used to calculate these values (Sing, 2005).
We have to note that the algorithms being studied depend solely on the topology of the network, 
implying  that  unconnected  nodes  and  very  small  components  cannot  transfer  the  score 
information  along  the  network.  Consequently,  only  the  largest  connected  component  of  the 
network was used for the evaluation (see Supplementary Table 3 for the number of proteins in 
the largest component of each network).
In the context of gene-phenotype association studies, obtaining negative data (proteins/genes 
that have no effect on a diseasee) is a challenge. We considered all proteins not associated with 
a particular disease as potential negative instances. Then, we used a random sampling of the 
potential  negatives to calculate an average score.  This score was defined as the score of  a 
negative instance.  We  calculated  as  many  scores  of  negative instances  as  seeds  (positive 
instances) in the evaluation set such that we had the same number of positive and negative 
scores.
Dependency of  prioritization  methods on network  features  and gene associations. We 
evaluated  the  dependency  of  the  five  prioritization  methods  implemented  in  GUILD on  the 
interaction and seed sets. This dependency was studied by modifying the data with three tests: 1) 
permuting  interactions  at  random,  2)  randomly  removing  interactions  of  the  network,  and  3) 
permuting the seeds at random. We tested the effect of the modifications on the bPPI and Goh 
networks using OMIM gene-phenotype associations. The degree of modifications ranged from 
10% to 100% for each network and seed set. Ensembles of 100 random networks and random 
seed sets were used to assess average prediction performance for each perturbation level. Thus, 
in each test, we used nine groups of networks or seed sets (corresponding to the percentage of 
perturbation,  10 to  100 with  the increments of  10)  and each group  contained 100  randomly 
perturbed networks or seed sets. For the first test, nine groups of 100 networks were generated 
by swapping the edges of the original network (randomly creating new edges and removing old 
ones), and each group contained a different number of random permutations corresponding to 
the 10% to 100% of the number of edges. For the second test, the edges were randomly deleted 
to create nine groups of 100 networks in which the number of deletions varied between 10% and 
100% of the number of edges. For the third test, a varying percentage of seed nodes (10% to 
100%) was replaced with non-seed nodes 100 times, yielding nine groups of seed sets and the 
percentage of non-seeds in each group ranged between 10 and 100. The prioritization methods 
were applied to these modified data sets and for each group the AUC averaged over the 100 
randomly modified networks or seed sets. 
Functional  enrichment  analysis. GO  terms  enriched  among  genes  corresponding  to  high 
scoring proteins in a network were identified using the FuncAssociate2.0 (Berriz et al., 2009) web 
service. Proteins in the network were mapped to the genes using the gene symbols provided by 
UniProt, and these symbols were fed to the web service. All genes in the network were used as 
the background gene list. A GO term was associated with the gene set, if and only if, the adjusted 
p-value associated with the term was less or equal to 0.05.
Defining robustness of a pathophenotype. As mentioned above, we applied network-based 
prioritization methods  on two  types of  perturbed networks  (random interaction swapping and 
interaction  removal)  and  analyzed  the  prioritization  accuracy  (AUC)  using  a  five-fold  cross 
validation scheme. For the phenotypic robustness analysis, we chose NetScore method since i) it 
had the highest prediction performance ii) it produced clusters that are functionally more relevant 
to the disease compared to the rest of the prioritization methods and iii) the method itself was not 
robust against perturbations (Figure 1 and Supplementary Figure 2).   We defined robustness 
based on the amount of interaction perturbation required to cause a “critical”  AUC change in 
network-based prioritization of a disease. For each disease, the critical AUC change was set as 
half of the AUC difference from expected AUC that would be obtained by random predictions. 
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That is, for each pathophenotype p, critical AUC was calculated using the following formula:
AUCcrit  p=
AUC init p – 0.5
2
A disease phenotype was called robust if the amount of interaction perturbation  (both interaction 
swapping and removal) required to cause a critical AUC change was lower than 50%. Similarly 
we called a disease phenotype non-robust if  the amount of interaction perturbation for critical 
AUC change was higher than 50%. 
For testing significance of differences in distribution of values between robust and non-robust 
diseases  we  used  Wilcoxon  rank-sum  test.  Alpha  values  were  set  to  0.05.  R  software 
(http://www.r-project.org) was used to compute statistics.
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Figure 1 Robustness of the methods with the perturbation of the edges of the bPPI network and 
initial disease-gene associations. The interactions of the bPPI network were perturbed (a) by 
swapping the links in order to make false interactions or (b) by removing links. Plots show 
the average AUC and confidence intervals  calculated for  the prediction of  gene-disease 
associations for  23 diseases using  NetScore (red),  NetZcore  (yellow),  NetShort  (green), 
Functional Flow (blue), and ToppGene (purple). The percentage of interactions swapped or 
removed varied between 0 and 80%. (c) Dependence on the number and quality of seeds. 
The average AUCs are given as the percentage of mis-annotated seeds goes from 0% to 
80%.
Figure 2 Change in the number and ratio of AD-related genes in the neighborhood of AD-seeds 
with respect to the amount of interaction permutation. The interactions of bPPI network were 
perturbed (a) by swapping the links in order to make false interactions or (b) by removing 
interactions.  The percentage of  interactions swapped or  removed varied between 0 and 
80%. The bars correspond to the number of genes whereas the line shows the ratio of the 
average number of AD-related genes in the neighborhood of AD-seeds to the number of all 
genes in the neighborhood.
Figure  3 Comparison  of  robust  and  non-robust  pathophenotypes  with  respect  to  (a) known 
disease annotations associated with disease, (b) the connectivity of these seeds (assessed 
by the average shortest path length between seeds),  (c) the modularity,  (d) the number of 
seed GO terms associated with the diseases,  (e) the number of  seed GO terms in the 
modules and (f) the number of all GO terms in the modules.
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Tables
Table 1. Network-based prioritization performance on the original and perturbed networks*.
Pathophenotype AUC (%) Pathophenotype AUC (%)
org.   crit. perm. del.  org.   crit. perm. del.  
alzheimer 78.3 64.2 62.5 62.8 lung cancer 85.0 67.5 65.8 68.4
anemia 70.3 60.2 56.4 57.9 lymphoma 79.7 64.9 62.3 71.8
asthma 31.7 n/a 34.8 28.4 mental retardation 56.3 53.2 46.6 45.3
ataxia 62.6 56.3 54.2 53.8 myopathy 86.0 68.0 67.3 72.0
breast cancer 76.7 63.4 70.7 75.8 neuropathy 42.5 n/a 38.1 33.2
cardiomyopathy 69.5 59.8 65.0 70.5 obesity 72.0 61.0 67.4 70.4
cataract 72.0 61.0 53.9 52.8 parkinson disease 80.0 65.0 70.9 78.5
diabetes 61.4 55.7 58.4 63.4 prostate cancer 68.0 59.0 52.7 62.7
epilepsy 62.1 56.1 47.4 47.4 schizophrenia 53.3 51.7 40.9 42.1
hypertension 70.0 60.0 47.7 51.8 spastic paraplegia 31.7 n/a 31.7 31.1
insulin 80.0 65.0 71.6 73.6 systemic lupus erythematosus 86.3 68.2 64.2 72.7
leukemia 84.6 67.3 75.8 81.6
* Table shows the AUC values using the original network (org.), the critical AUC values (crit.) and 
the AUC values using perturbed networks (perm.; 50% of interactions permuted, del.; 50% of 
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Figure 3
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Supplementary material  for  Guney E.  and Oliva  B.,  Robustness of  Network-based Disease 
Gene Prioritization Methods Points to Pathophenotypic Plasticity
SUPPLEMENTARY RESULTS
Investigating  functional  modularity  of  the  top-ranking  genes  identified  by  the  prioritization 
methods
Cells  exhibit  a  modular  nature  in  which  genes  are  organized  into  various  interconnected 
pathways and such organization of  genes is  often attributed as an essential  component  of 
robustness [1]. In this work, we questioned whether the prioritization methods identified groups 
of genes that were functionally associated with the disease phenotype. First, we carried out a 
module-based  functional  enrichment  analysis,  using  top  scored  nodes  associated  with  a 
disease identified by network-based prioritization approaches. Then, we examined the extent to 
which  these  prioritization  algorithms  were  able  to  discover  functions  implicated  in  complex 
genetic disorders. We acquired GO terms that are significantly enriched in the set of genes 
associated  with  the  disease  (seed  GO  terms).  We  used  five  network-based  prioritization 
approaches to score proteins associated with diseases from the OMIM database. We also used 
a trivial prioritization approach where all neighbors of the seeds were prioritized for the same 
pathophenotype (direct neighborhood). Next, we applied a clustering protocol based on MCL 
[2], a random-walk based graph clustering algorithm, to the sets of highly scored nodes or the 
neighbors of the seeds. For each disease, this procedure produced a set of clusters of proteins 
potentially implicated in the pathology of the disease. A cluster was potentially implicated in the 
disease, if and only if it contained two or more seeds (see Supplementary Methods for details). 
We checked the percentage of seed GO terms among all GO terms significantly enriched in 
these clusters, based on the GO terms enriched among the genes in the clusters. The number 
of  clusters was smaller  when prioritizing with NetScore and NetZcore than with  the rest  of 
methods  (Supplementary  Figure  2a).   Moreover,  the  genes  in  the  clusters  prioritized  by 
NetScore and NetZcore were slightly more enriched in seed GO terms, suggesting that they 
could identify genes more relevant to the disease, these being either seeds or genes involved in 
similar  functions  (Supplementary  Figure  2b).  In  particular,  the  GO  term  enrichment  in  the 
clusters when prioritizing with the neighborhood approach was very low, while the number of 
clusters was large. We wish to note that if the number of clusters is large, the seeds may be 
functionally spread among several sets. In contrast, if the number of clusters is small, the genes 
(or proteins) in these clusters have similar functions that may characterize the main functional 
features of the disease. Our results showed that NetScore and NetZcore tended to form a small 
set of functionally coherent groups. These functionally coherent groups of genes are likely to 




Network-based disease-gene prioritization methods
We recently proposed three disease-gene prioritization methods that use known disease-gene 
annotations and protein-protein interaction network to rank genes (or their proteins) with respect 
to a given phenotype [3,4]. The first method, named NetShort, considers not only the number of 
links that reach to the phenotype-associated node but also the number of phenoype-associated 
nodes that are included in the path. This is achieved by modifying the weight of the links in 
shortest path algorithm such that the links connecting seed nodes are shorter than the links 
connecting non-seed nodes. The second method, NetZcore, iteratively assesses the relevance 
of a node for a given phenotype by averaging the normalized scores of the neighboring nodes in 
a network. The normalized scores for each node is calculated using observed scores of the 
same  node  in  a  catalog  of  random networks  that  have  the  same topology  as  the  original 
network. Finally, the third method, NetScore considers multiple shortest paths (if exist) from the 
source of information to the target for each node and ignores all other paths between them. All 
of these algorithms were implemented in C++ (requires GNU C++ compiler and GNU make) and 
freely available at http://sbi.imim.es/GUILD.php .
Identification of clusters associated with the disease. We defined two types of sub-networks 
to compare the enrichment of GO terms and specific functions in putative pathways: 1) a trivial 
approach also named “neighboring” used the nodes of a network formed by seeds of a disease 
and their interaction partners; and 2) a more sophisticated approach, using the highly scored 
nodes (proteins) of the network identified by a prioritization method. The edges of these sub-
networks  were  taken  from the  original  network,  using  all  edges  that  connected  any  of  the 
selected nodes.   For  assigning GO terms we used the genes that  produce these selected 
proteins. We identified clusters in these sub-networks using the Markov cluster (MCL) algorithm 
[2].  The inflation parameter  of  MCL was chosen to be  1.7,  the optimum value obtained by 
Brohee and van Helden [5]. Only the clusters that contain two or more proteins translated by 
disease-associated genes were taken into consideration. We then determined the percentage of 
GO terms significantly  enriched in  the set  of  genes associated with the disease (seed GO 
terms) among all GO terms significantly enriched in identified clusters. 
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SUPPLEMENTARY FIGURES
Supplementary Figure 1 Robustness of the methods with the perturbation of the edges of the 
Goh network. Plot of the average AUC (shown in bars) and confidence interval (shown with 
error lines) calculated for the prediction of gene-disease associations by NetScore (red), 
NetZcore (yellow), NetShort (green), Functional Flow (blue), and ToppGene (purple). The 
interactions of Goh network were perturbed (a) by swapping the links in order to make false 
interactions or (b) by removing interactions. The percentage of interactions swapped or 
removed varied between 0 and 80%. (c) Plot of the average AUC and confidence intervals 
calculated  for  the  prediction  of  gene-disease  associations  as  the  percentage  of  mis-
annotated seeds goes from 0% to 80%.
Supplementary  Figure  2 Module-based  functional  enrichment  analysis  of  prioritized 
subnetworks.  (a) Number  of  modules  identified  in  the neighborhood of  known disease 
associations  (N.hood)  and  in  high  scoring  subnetworks  identified  by  Functional  Flow 
(Func.Flow), NetScore, NetZcore, NetShort, or ToppGene (T.Gene) prioritization methods. 
(b) Percentage of seed GO terms (GO terms significantly enriched in the set of genes 
associated with the disease) among all GO terms significantly enriched in the identified 
modules. 
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Supplementary Figure 3 AUC change at different levels of perturbations in the network for 
robust pathophenotypes.  Solid lines correspond to AUC of the disease when NetScore 
prioritization  method  is  applied  to  the  interaction  network  whose  edges  are  randomly 
swapped  and  dashed  lines  correspond  to  AUC of  the  disease  when  the  prioritization 
method is applied to the interaction network whose edges are randomly deleted.
Supplementary Figure 4 Heatmap representation of Jaccard indices calculated for every pair 
of pathophenotypes using GO terms in the high scoring (top 5%) modules identified by 
NetScore prioritization method. 
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Supplementary Figure 5 GO terms shared in the high scoring modules of at least 3 diseases 
(a) in the robust diseases category (b) in the non-robust diseases category.
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SUPPLEMENTARY TABLES
Supplementary Table 1 The list  of  the diseases used in  this  study,  the number of  genes 
associated with them and the number of gene products corresponding to these genes in 
the interaction network.
# of genes
# of gene products covered by the largest 
component (LCC) of the interaction network
Phenotype bPPI Goh
alzheimer 48 18 17
anemia 129 73 54
asthma 47 16 12
ataxia 131 44 30
breast cancer 70 35 29
cardiomyopathy 138 51 43
cataract 85 25 20
diabetes 182 70 63
epilepsy 139 33 26
hypertension 51 19 15
insulin 54 14 13
leukemia 162 102 75
lung cancer 43 22 16
lymphoma 39 23 22
mental retardation 257 64 46
myopathy 102 38 30
neuropathy 100 37 26
obesity 59 25 22
parkinson disease 52 16 13
prostate cancer 63 25 23
schizophrenia 45 19 13
spastic paraplegia 66 16 14
systemic lupus 
erythematosus 43 21 14
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Supplementary  Table 2 The  interaction sources  used to  create  the  human protein-protein 
interaction network.








Goh [6] Interactions collected from literature (i.e. 
large-scale Y2H experiments by Rual et 





DIP [10] January 2009 11250 59220
HPRD [11] September 2007
IntAct [12] January 2009
MIPS (MPACT) [13] October 2008
BioGRID [14] 2.0.49
Supplementary  Table  3 Module-based  functional  enrichment  analysis  of  prioritized 
subnetworks.
Provided as a separate XLS file.
Supplementary Table 4 Modules and GO terms enriched in the prioritized subnetworks.
Provided as a separate XLS file.
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ABSTRACT
Determining  genetic  factors  underlying  various  phenotypes  is  hindered  by  the  involvement  of  multiple  genes  acting 
cooperatively.   Over the past  years,  disease-gene prioritization has been central  to identify genes  implicated in human 
disorders. Special attention has been paid on using physical interactions between the proteins encoded by the genes to relate 
them with diseases. Such methods exploit the guilt-by-association principle over the protein interaction network to uncover 
novel disease-gene associations. These methods rely on the proximity of a gene in the network to other genes known to be 
involved in the same phenotype and typically require a known set of initial associations. Here, we present GUILDify, an 
easy  to  use  web  server  for  the  phenotypic  characterization  of  genes.  Available  at  http://sbi.imim.es/GUILDify.php, 
GUILDify offers a whole genome protein-protein interaction network-based prioritization where the initial phenotype-gene 
associations  are  retrieved  via  free  text  search  on  biological  databases.  GUILDify  web  server  does  not  restrict  the 
prioritization to any predefined phenotype and supports multiple species.
INTRODUCTION
During the past decade, disease-gene prioritization has been central to research efforts in the field of human genetics. The 
promise of suggesting novel associations for genetic disorders with implications to therapeutical improvements has yielded 
a broad spectrum of computational tools (1, 2). These tools take into account a diverse set of data types such as functional  
annotation, gene expression, sequence properties, orthology, text mining and protein-protein interactions to extend known 
disease-gene associations. Given that the genetic factors deriving a phenotypic trait usually consist of more than a single 
gene, a special attention has been paid on using physical interactions between the products of these genes to relate them 
with diseases (3, 4).
Following  the  emergence  of  high  throughput  interaction  detection  experiments,  protein  interaction  network-based 
approaches have been employed to prioritize genes involved in various diseases (5–10). Network-based methods exploit the 
“guilt-by-association”  principle  over  the  network  topology  to  uncover  new  disease-gene  associations.  The  guilt-by-
association principle suggests that the genes whose products (proteins) interact with the products of known disease genes 
are more likely to be disease genes (11, 12). The methods using global topology of the network has been demonstrated to 
predict disease genes more accurately compared to methods that use only local neighborhood of genes (8). Recently, we 
proposed three novel  algorithms for genome-wide prioritization of disease-genes using protein-protein interaction (PPI) 
networks (7) and showed that a consensus method combining these algorithms, outperformed the state-of-the-art global 
network  topology-based  prioritization  methods  (Guney  and  Baldo,  manuscript  in  preperation)  using  the  disease-gene 
associations in OMIM database (13).
All of the network-based methods rely on the proximity of a gene in the network to other genes known to be involved in the 
same phenotype, thus require a known set of initial associations (seed genes). Among available global topology network-
based tools, GeneWanderer uses known disease-gene annotations in OMIM database (13) and prioritizes the genes lying 
under a given genomic interval by applying random walk with restart  algorithm (14).  Similarly, PRINCIPLE retrieves 
disease-gene annotations from OMIM for a disease term provided by the user and ranks the genes by network propagation 
algorithm (15). In ToppNet a set of genes provided by the user are fed to PageRank with priors (or to a similar) algorithm to 
rank another set of genes provided by the user (16). PINTA considers differentially expressed genes in disease-specific 
expression data for the phenotype of interest  as seed genes and employs either diffusion based or random walk based 
algorithm for whole genome or candidate genes provided by the user (17). 
Publicly available biological data repositories can also be utilized for mining initial phenotype-gene associations required by 
network-based prioritization methods without restricting to any predefined phenotype. Considering the limited availability 
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of convenient interfaces that bridge network-based prioritization algorithms to end users, we present GUILDify, a whole 
genome  PPI  network-based  prioritization  server  for  phenotypic  characterization.  GUILDify  ranks  the  genes  for  their 
relevance to a given phenotype. It supports multiple species and can retrieve initial phenotype-gene associations (seeds) via 
free text search on biological databases for any given phenotype. The genes extracted from biological databases and/or 
provided by the user are fed to the network-based prioritization methods we have developed recently. GUILDify is available 
at http://sbi.imim.es/GUILDify.php (free and open to all users and there is no login requirement). 
GUILDIFY WORKFLOW
The  workflow of  GUILDify  web  server  consists  of  three  simple  steps  (see  Supplementary  Figure  1  for  a  schematic 
overview). In the first step, the user enters some text describing the phenotype of interest and chooses the organism for 
which she wants to run whole genome prioritization based on protein-protein interaction networks. In the next step, among 
all the proteins encoded by the genes that have been found to be associated with the phenotype, the user chooses which 
proteins  to  designate as  seeds (source of  information)  in  network-based  prioritization.  At  this  step,  the user  may add 
additional  genes (and their products) that  are not listed by the text-based search at the first step.  In the final step,  the 
network-based prioritization algorithm is run and the ranking of the products of genes is displayed to the user. The ranking 
represents the predicted level of association with the phenotype of interest.
RETRIEVING PHENOTYPE-GENE ASSOCIATIONS
When a query is  made through GUILDify web interface (any text  describing a phenotype such as  disease,  biological 
function or pathway), the query is tokenized into keywords. The descriptive fields of UniProt (both Swissprot and Trembl) 
database --“description”, “disease”, “function” and “keyword”-- are searched for matching keywords. In addition to these 
descriptive fields in UniProt, OMIM disorder names and GO term names are searched for matching keywords. GUILDify 
also supports quoted phrases to query the occurrence of a group of words in biological databases. Therefore to describe a 
phenotype that consists of multiple words, the words should be quoted.
GUILDify keeps a local copy of these databases for fast search and retrieval of information. Once the genes matching to the 
query  are  identified,  GUILDify  uses  BIANA (18),  a  tool  that  integrates  biological  data  spread  over  various  publicly 
available proteomics and interaction databases, to list proteins encoded by the matching genes. The BIANA knowledge base 
integrated in GUILDify consists of the following biological data repositories (all downloaded after May, 2011): UniProt 
(19), HGNC (20), DIP (21), HPRD (22), IntAct (23), MINT (24), MPact (25), BioGRID (26), BIND (27). The entries in 
these  databases  are  unified  using  common  identifiers  such  as  UniProt  Accession,  protein  sequence  and  Entrez  Gene 
Identifier.
Though literature provides an initial catalog of phenotype-gene annotations, these annotations may not always be complete. 
Furthermore, in some cases the annotation provided in the literature could be spurious or the user simply may not want to  
include these annotations in the whole-genome prioritization. Thus, the users may provide any number of genes that are not 
listed by GUILDify and/or may choose to use a subset of the listed genes. 
WHOLE GENOME PRIORITIZATION USING PPI NETWORK
Given a set of initial phenotype-gene associations (seeds), GUILDify maps these associations onto a genome-wide PPI 
network and runs a global topology-based prioritization algorithm developed recently in our group under the context of 
GUILD framework (7). The species-specific PPI network is generated using the interaction databases integrated in BIANA 
(listed above). GUILD (Genes Underlying Inheritance Linked Disorders) implements three algorithms (see Supplementary 
Material) to prioritize genes potentially involved in diseases using  a priori gene-disease associations and protein-protein 
interactions.  GUILDify uses a consensus method combining the scores of the former three algorithms, for scoring the 
relevance of all protein in the interaction network (see Supplementary Material for details). 
OUTPUT
GUILDify outputs a likelihood score (GUILD Score) associating the gene product with the phenotype provided by the user 
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for each gene product in the PPI network. In addition to GUILD Score, descriptive information of the gene products such as 
UniProt Accession,  gene symbol,  Entrez gene id and description is included in the output. The files containing all of this 
information as well as the seed proteins used in the prioritization method can be downloaded via the links provided on the 
result page.
IMPLEMENTATION
The interface of the web server is built using Pyramid, a Python platform for web programming, with an emphasis on 
simplicity  and  ease-of-use.  MySQL is  used  to  store  and  retrieve  biological  data.  The  prioritization  algorithms  are 
implemented  in  C++  and  a  two-node  cluster  is  used  on  the  web  server  to  schedule  job  requests.  See  BIANA 
http://sbi.imim.es/web/BIANA.php and GUILD http://sbi.imim.es/web/GUILD.php for the details on their implementation. 
GUILDify is  designed to  be as  simple as  possible.  Many algorithmic  details  such as  internal  parameters  used  by the 
prioritization algorithms are hidden from the user. These parameters are chosen the values that are shown to be optimum on 
a large data set of disease phenotypes under the context of GUILD project. The users that are interested in using user-
defined parameters are advised to refer to download stand-alone software provided in the GUILD project page. 
VALIDATION
We confirmed the validity of our predictions using Alzheimer's disease phenotype in human. For Alzheimer's disease, we 
used  differentially  expressed  genes  in  Alzheimer's  disease  identified  in  a  previous  study  (28) as  true  positives.  True 
negatives were randomly selected among genes whose association to the phenotype is unknown (such that there was an 
equal number of true negatives as there were true positives). The Kratuhammer data set contained 60 genes and only one of 
them was not  in the PPI network. After  removing 11 seeds listed by GUILDify,  the remaining 48 genes  used for  the  
validation. On this data set, the precision obtained by using “alzheimer” keyword on the web server was 83% at 71% 
sensitivity level. 
COMPARISON WITH EXISTING WEB SERVICES
In order to compare GUILDify with existing network-based prioritization web services, we checked the coverage of the 
genes in the aforementioned data set among the top ranking genes provided by these services (Table 1). The web services 
included  in  the  comparison  were  ToppNet  and  PRINCIPLE. GeneWanderer  is  excluded  from the  comparison since  it 
prioritizes  the genes  only under a  given linkage interval.  PINTA is also not  taken into consideration since it  requires 
phenotype-specific expression data. 
We used the seeds identified by GUILDify as training genes and all the genes in the PPI network as test genes in ToppNet. 
We ranked the genes in the test set  using PageRank with priors algorithm with the default parameters and the built-in 
interaction network of ToppNet. Since ToppNet does not provide a ranking for the training genes, we assumed the best case 
scenario and considered all the seed genes contained in the benchmarking set (11 genes) as having the highest rank. In the 
Cytoscape plugin of PRINCIPLE, we chose “Alzheimer Disease (AD)” and only modified the k-cutoff parameter (number 
of top genes to output) by setting it to its maximum value such. Then we considered all the top ranking genes and their 
neighbors identified by the plugin using network propagation algorithm and the interaction network integrated into the web 
service.
Table 1. Comparison of web services with respect to the number of benchmark genes covered among the top ranking genes.
Web Service Number of top ranking genes considered
100 250 500 1000
GUILDify 11 17 26 34
ToppNet 16 25 31 37
PRINCIPLE 13 21 27 35
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CONCLUSION
Phenotypic characterization of genes plays a crucial role in explaining the mechanisms behind biological processes.  We 
have developed GUILDify, a free and easy to use web server for whole genome prioritization of genes using PPI networks. 
For a given phenotype, GUILDify uses descriptive fields in several proteomics and genomics databases in combination with 
network-based prioritization methods and provides a genome-wide ranking. The ranking represents the relevance to the 
phenotype of interest and can be used to shortlist the set of candidate genes that needs to be further validated. Though the 
prediction performance is far from perfect, GUILDify serves to generate a meaningful ranking among genes just by 
applying PPI network-based whole genome prioritization over the data extracted from biological databases.  
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SUPPLEMENTARY DATA
This text contains the supplementary information for the manuscript entitled “GUILDify: A web server for phenotypic  
characterization of genes through biological data integration and network-based prioritization algorithms” by Emre Guney, 
Javier García-García and Baldo Oliva.
GUILDIFY WORKFLOW
Supplementary Figure 1. Schematic overview of GUILDify workflow. (1) A text describing the phenotype of interest is 
queried over several genomics and proteomics databases and the genes (proteins) matching with the input query for the 
species of interest are listed. (2) The seed genes (proteins) are chosen among these and mapped onto the PPI network. At 
this step, the user may add additional genes (proteins) that are not listed by the text-based search at the first step. (3) Using 
the seeds and species-specific PPI, all  the genes (proteins) in the network are prioritized and the ranking of the genes 
(proteins), corresponding to the predicted level of association with the phenotype of interest, is displayed to the user. 
PRIORITIZATION METHODS USED IN GUILDIFY
GUILDify uses  NetCombo algorithm, a  consensus method which combines  the following three prioritization methods: 
NetShort,  NetZcore and  NetScore  (1). NetShort incorporates “phenotypic-relevance” of the path between a node and the 
nodes of a given phenotype by considering not only the number of links that reach to the phenotype-associated node but 
also the number of phenoype-associated nodes that are included in the path. Algorithmically, this is achieved by modifying 
the weight of the links in shortest path algorithm such that  the links connecting seed nodes are shorter than the links 
connecting non-seed nodes.  NetZcore iteratively assesses the relevance of a node for a given phenotype by averaging the 
normalized scores of the neighboring nodes in a network. The normalized scores for each node is calculated using observed 
scores of the same node in a catalog of random networks that have the same topology as the original network (yielded by 
swapping nodes in the original network). NetScore is based on the propagation of information (i.e. data packets) through the 
nodes in the network by considering multiple shortest  paths (if exist) from the source of information to the target and 
ignoring all other paths between them. In addition to the scores of the nodes, the data packet contains the weight of the path 
that the packet has traveled. Iteratively, a score is calculated for each node using the packets it has received from shortest 
paths (more than once if multiple shortest paths exist) weighted by the edge weights along these paths. NetCombo combines 
NetScore, NetShort and NetZcore in a consensus scheme by averaging the normalized score of each prioritization method. 
We tested the prioritization methods we proposed in GUILD using multiple gene-disease association data sets (from OMIM 
database) and protein-protein interaction networks. In this genome-wide analysis, NetCombo outperformed state-of-the-art 
network-based  prioritization  methods  such  as  Functional  Flow,  PageRank  with  Priors,  Random walk  with  restart  and 
Network propagation (manuscript under preparation). 
90
COMPARISON WITH EXISTING WEB SERVICES
We used the seeds identified by GUILDify as training genes and all the genes in the PPI network as test genes in ToppNet 
(2). We ranked the genes in the test set using PageRank with priors algorithm with the default parameters and the built-in 
interaction network of ToppNet. Since ToppNet does not provide a ranking for the training genes, we assumed the best case 
scenario and considered all the seed genes contained in the benchmarking set (11 genes) as having the highest rank. In the 
Cytoscape plugin of  PRINCIPLE  (3), we chose “Alzheimer  Disease  (AD)” and  only modified  the  k-cutoff  parameter 
(number of top genes to output) by setting it to its maximum value. Then, we considered all the top ranking genes and their 
neighbors identified by the plugin using network propagation algorithm and the interaction network integrated into the web 
service.
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Cancer is produced by perturbations affecting several genes and pathways. Environmental stimuli trigger uncontrolled cell 
growth and invasion of other tissues. Understanding cancer progression requires a profound knowledge of the pathways 
involved in the communication between proteins and genes at a systems level. Consequently, protein-protein interaction 
networks play an important role in delineating cancer related pathways. Our understanding of cancer has evolved towards 
the co-operation of  groups of  genes  that  constitute  pathways.  In  this  chapter,  we describe the characteristics  of genes 
involved in cancer and the relationships between them in the context of the protein-protein interaction network. We also 
explain  several  methods  to  predict  novel  candidates  that  are  potentially  involved  in  cancer  and  its  progression  using 
topological information encoded in the protein-protein interaction network. Towards developing effective network-based 
therapeutics, we give details of identifying dysregulation patterns in cancer using protein-protein interaction networks with 
an emphasis on the underlying mechanisms of progression in metastatic breast cancer.
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Cancer is the outcome of perturbations in the orchestral activity of genetic elements. Environmental stimuli disturb the 
genetic regulation circuitry composed of such genetic elements and trigger uncontrolled cell growth and invasion of other 
tissues (Hanahan and Weinberg, 2011). These consequences can only be counteracted through profound understanding of 
the pathways underlying the progression of cancer at a systems level (Laubenbacher, et al., 2009).  This argument follows 
from recent works showing that interactions between gene products mediate pathways involved in cancer (Jonsson and 
Bates, 2006; Vogelstein and Kinzler, 2004). Therefore, studying dysregulation patterns of the protein-protein interaction 
network is key to delineate cancer related pathways (Mani, et al., 2008) and to develop effective treatment strategies such as 
network-based therapeutics (Russell and Aloy, 2008).
Among variety of molecular mechanisms involved in cancer, gene regulation, signaling and cell metabolism pathways as 
well as the cross-talk between them are the most relevant ones (Hanahan and Weinberg, 2011). We can perfectly assume that 
cancer originates from a single cell.  Due to a change in the expression behavior of one or more genes involved in the 
regulation of the cell growth and differentiation, the cell starts abnormally replicating itself through mitosis. Effected genes 
are classified in two categories depending on their functional roles: oncogenes and tumor suppressor genes. Oncogenes 
promote cell growth and reproduction hindering the cell from going programmed cell death (apoptosis), whereas tumor 
suppressor genes inhibit cell division and survival. The failure in the cell cycle regulation is typically caused by mutations in 
several oncogenes and/or tumor suppressor genes. These mutations rapidly accumulate over the following generations of 
cells. This faulty group of cells constitutes the primary tumor. Cells of the primary tumor can travel within the body through 
the lymph and blood and may establish secondary (metastatic) tumor in a location different than the tissue from where it 
was originated.  Metastatic  colonization requires  adaptation to  the  microenvironment  of  the distant  organ  site  and this 
introduces a constraint on the tissues where metastatic cells can possibly invade (see reviews (Gupta and Massague, 2006; 
Steeg, 2006; Valastyan and Weinberg, 2011)). Furthermore, the adaptation mechanism varies depending on the tissue of 
origin of the primary tumor cells and the tissue (or tissues) where these primary tumor cells metastasize (Valastyan and 
Weinberg, 2011). That is, the genetic and epigenetic programs employed by metastatic breast cancer cells in the bone are 
different than the ones in metastatic prostate cancer cells or those metastasizing in brain, liver or lungs. Recent studies 
demonstrated that the invasion capacity of cancer cells are not limited to primary tumors, also metastatic tumors have the 
ability of infiltrating back to their primary tumors (Comen, et al., 2011; Valastyan and Weinberg, 2011). 
Invasion of distant organs through metastatic colonization has especially attracted attention due to almost 90% of causalities 
being attributed to metastases rather than the primary tumors from which they originated (Gupta and Massague, 2006). 
However, the cellular processes governing metastases are still far from understood. The two main drawbacks in the study of 
cancer progression are cellular heterogeneity within tissues and genetic heterogeneity across patients (Chuang, et al., 2010). 
Cellular heterogeneity between the cells of the same tissue implies that they don’t have a well-defined distinct phenotype for 
a specific  cancer type.  Genetic heterogeneity refers to the condition where different  patients have different  expression 
patterns  for  the  same  gene.  This  clearly  implies  two different  perspectives  describing  cancer  progression:  changes  of 
expression  of  few  genes  on  one  side  and  the  pathways   (i.e.  interaction  networks)  affected  by  them  on  the  other. 
Consequently, the impact of a small perturbation is amplified to the point that the survival of a complex system, such as an 
organism, is jeopardized. The analysis of gene expression has provided insights into the elements that change their patterns 
of expression during the progression of various cancer types (Quackenbush, 2006). However, to be able to characterize the 
associated cellular processes, we need to account for the complex interactions between these genetic elements. 
Advances  in  biological  data  collection  and  bioinformatic  techniques  gave  rise  to  more  systematic  approaches  for  the 
interpretation of  the data.  Systems biology fundamentally challenges the gene centric view of cancer.  This view takes 
advantage of the present increase and availability of data describing biological molecules and their relationships. Through 
integration  of  different  data  sources  such  as  protein  sequence,  gene  expression  and  protein-protein  interactions,  our 
understanding  of  cancer  has  evolved  rapidly  towards  the  co-operation  of  groups  of  genes  that  constitute  pathways. 
Consequently, the past decade witnessed a brand new perspective, named network biology. In network biology, genes, their 
products and the interactions between them are studied within the framework of the biological system as a whole.
In this chapter, we first delineate the characteristics of genes involved in cancer and the relationships between them in the 
context  of  protein-protein  interaction  (PPI)  network  (Section  2.2).  Then,  in  Section  2.3  we  explain  several  network 
modeling approaches that incorporate genomics data, complementing the networks created by PPIs. In the following section 
(Section 2.4), we describe methods to predict novel candidates that are potentially involved in cancer and its progression 
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using topology information encoded in the PPI network. Next, we give details of several network biology approaches to 
identify dysregulation patterns in cancer and how to use them to improve our knowledge on the prognosis (Section 2.5). In 
Section 2.6, we focus on a number of works that shed light on the underlying mechanisms of progression in metastatic 
breast cancer. Finally, we provide an outlook on the use of network medicine approaches towards developing effective 
treatment strategies in Section 2.7. The reader, unless familiar with the topics that are mentioned throughout the text, such as 
the integration of biological data or graph theory concepts, is advised to refer to Boxes 1, 2 and 3 where concise information 
on these subjects are provided.
2. Protein-protein interaction networks underlying cancer
Coordinated relationships between biological  molecules help to describe a particular phenotype. Cancer can be studied 
under the same approach. PPI networks provide a framework to study the functional relationships among such biological 
molecules (Barabasi and Oltvai, 2004). For instance, topological features of gene and protein interaction networks helped 
attributing  functions  to  genes  whose  functions  were  not  characterized  (Schwikowski,  et  al.,  2000).  Studying  network 
properties of human genes also provided valuable insights in diseases and cancer in particular (Ideker and Sharan, 2008; 
Vidal, et al., 2011). 
The first step in the systematic study of relationships between genetic elements is the integration of data describing various 
aspects of the biomolecules as well as the links between them (e.g., physical or functional associations). With the recent 
emergence of high-throughput interaction detection experiments, a substantial amount of data of physical PPIs in human 
became publicly  available  (Dreze,  et  al.,  2010;  Venkatesan,  et  al.,  2009).  These  interaction  maps  offer  an  invaluable 
resource for network-based studies. However, they are incomplete, they content a large amount of noise (false interactions) 
and  occasionally  biased  towards  highly  studied  proteins  (Schwartz,  et  al.,  2009;  Venkatesan,  et  al.,  2009).  Thus,  PPI 
networks by themselves provide only a partial view of the complex biological processes. A comprehensive understanding of 
complex  diseases,  such  as  cancer,  lies  beneath  the  integration  of  biological  data  at  different  levels  (genomics, 
transcriptomic,  proteomic and metabolomic)  and the  analysis  of  the  relationships  between biomolecules  in  a  dynamic 
context (Joyce and Palsson, 2006; Rhodes and Chinnaiyan, 2005, Xia, 2011 #198). Several data repositories widely used in 
the context of network-based cancer studies are given in Box 1.
10% of human genes are estimated to contribute to oncogenesis (Strausberg, et al., 2003), in fact this seems to be a general 
trend in all diseases (Amberger, et al., 2009). Cancer genes have shown to be distinguishable from normal genes based on 
structural, functional and evolutionary properties (Furney, et al., 2008). Nonetheless, cancer is typically seen as a disease 
where many different perturbations produce a similar phenotype due to the underlying interrelated pathways (Barabasi, et 
al., 2011; Wood, et al., 2007). Incorporating PPI information is indispensable to characterize such pathways. Topological 
characteristics of genes implicated in cancer have been thoroughly investigated during the past years. Wachi et al. (Wachi, et 
al.,  2005) analyzed cancer  tissue samples  and normal tissue samples surrounding the tumor from 5 patients with lung 
squamous cancer (a subtype of lung cancer associated with smoking) in the framework of a protein interaction network. The 
network contained known physical protein-protein interactions and predicted interactions using interology (via transferring 
interactions  from model  organisms).  Their  analysis  showed  that  genes  that  were  up-regulated  in  cancer  were  highly 
connected in the network (i.e. their interaction partners were also up-regulated genes).  Furthermore, these up-regulated 
genes were identified to be central, where centrality was defined as the enrichment of up-regulated genes in each k-core in 
the network (refer to Box 2 for the basic concepts in graph theory). 
Similarly, Jonsson and Bates (Jonsson and Bates, 2006) used a larger human interactome constructed by interology and a 
comprehensive census of human cancer genes from the work of Futreal et al. (Futreal, et al., 2004) to analyze network 
positions of cancer related genes. They revealed that products of genes that were susceptible to mutations leading to cancer 
had the predisposition to interact with each other twice as much as the products of non-cancer genes. They also identified 
commonalities among the nodes of the network by clustering the network into overlapping subnetworks (union of k-cliques 
that share k-1 nodes with each other). The cancer proteins were found to be involved in larger groups than non-cancer 
proteins. Moreover, they were observed to reside in the overlapping parts of the clusters more often than their non-cancer 
counterparts. 
In a network centric analysis of gene-disease associations for 22 disorder classes from Online Mendelian Inheritance in Man 
(OMIM) (Hamosh, et al., 2005), Goh et al. (Goh, et al., 2007) showed that products of genes involved in the same disorder  
class were predisposed to interact with each other. These genes constituted functional modules enriched in Gene Ontology 
(GO) (Ashburner, et al., 2000) terms. Genes from the same disorder class were also more likely to be homogeneously co-
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expressed in tissues related to the pathology. Although, in general, most disease genes were found to be non-essential and 
had no tendency to encode hubs in the network, their analysis on somatic cancer genes demonstrated that cancer genes 
likely encoded protein-hubs, pointing out the functional and topological centrality of the cancer genes.
Kar and colleagues (Kar, et al., 2009) overlaid structural information of proteins and their binding sites on top of a protein-
protein interaction network. They analyzed the structural properties of binding sites of cancer-related proteins.  They started 
with the human PPI network used by Jonsson and Bates (Jonsson and Bates, 2006) (13,584 nodes and 85,083 edges) and 
mapped known and predicted protein interfaces (from PDB (Berman, et al., 2000) and PRISM (Ogmen, et al., 2005) web 
server)  on  the  protein  interaction  network.  The  resulting  network  contained  534  nodes  and  549  edges  where  edges 
corresponded to structurally characterized interaction sites. Their analysis revealed that cancer-related proteins had smaller, 
more planar, more charged and less hydrophobic binding sites than non-cancer proteins. Moreover, cancer-related protein-
hubs in the interaction network tended to be essential, to interact with each other and to employ distinct interfaces in their 
interactions with their partners (multi-interface hubs) compared to their non-cancer counterparts. Based on their findings, 
the authors claimed that cancer proteins usually employ transient interactions and are more likely to be involved in multiple 
pathways. They further showed that such structural properties of binding interfaces could be used to classify the cancer 
phenotype in which the protein was implicated (e.g. leukemia, breast cancer or colorectal cancer) with accuracies ranging 
between 60-70% depending on the cancer type (refer to Box 3 for definitions of metrics used in the evaluation and classifier 
performance). Their predictions could help efficiency of drug discovery by suggesting potential targets to be used in cancer 
therapy (Fry and Vassilev, 2005).
3. Complementary network models based on cancer mediated gene expression changes
Network models have been employed to describe and infer relationships between co-expressed genes involved in cancer. 
Complementary to physical interaction networks, such models capture gene expression changes mediated by the disease. 
Ergun et al. (Ergun, et al., 2007) created a network model of regulatory interactions using 1144 whole-genome expression 
profiles spanning various cancer types such as adrenal, brain, breast, leukemia, lung, prostate and thyroid. The influence of 
all transcript concentrations and external factors were taken into consideration to model the transcript synthesis rate and 
infer the regulatory network using a reverse engineering approach. The regulatory network was then used to attribute genes 
to  the  progression  of  prostate  cancer.  Using  14  non-recurrent  primary  and  9  metastatic  prostate-cancer  samples,  they 
identified the genes in the regulatory network with significant  expression changes as the genetic mediators of prostate 
cancer.  Their  results  demonstrated the role of the androgen receptor pathway in the progression of  metastatic prostate 
cancer.
Based on the hypothesis that genes implicated in cancer initiation and progression show dysregulated interactions with their 
molecular  partners,  Mani  et  al. (Mani,  et  al.,  2008) emphasized the identification of  molecular  interactions  that  were 
significantly dysregulated in a particular phenotype. They used a genome-wide cellular interaction network for human B-
cells involving several key molecular interaction types such as transcriptional interactions, signaling events, and complex 
formation in combination with microarray expression profiles from normal, tumor-related, and experimentally manipulated 
B cells. In this network they used a naïve Bayes integration approach to incorporate protein-protein interactions, protein-
DNA interactions  and  regulatory  interactions  between  two  genes  modulated  by  a  third  gene  product.  The  method 
distinguished two types of changes in the background regulatory network, namely loss and gain of correlation, which were 
caused due to the genetic perturbations in the phenotype of interest.  If  two connected genes  in the network were not 
correlated,  according to the samples  of the phenotype,  the link was classified as  loss  of  correlation. Similarly,  if  two 
unconnected genes in the network were correlated in the phenotype, the link between these genes was classified as gain of 
correlation. The change of correlation between two genes was assessed by the difference of mutual information (calculated 
with the expression profiles of these genes under all conditions and those with the phenotype of interest). Next, the genes 
were  ranked  based  on  the  enrichment  of  gain  and  loss  of  correlation  events  under  the  phenotype  of  interest.  They 
highlighted  several  highly  ranked  genes  such  as  BCL2,  SMAD1 in  Follicular  lymphoma;  MYC,  MTA1 in  Burkitt's 
lymphoma; and CCND1, HDAC1 in mantle cell lymphoma where all of these genes had evidence in the literature for their 
association to the phenotype. Using an approach solely dependent on the differential expression of the genes could not have 
identified some of these genes otherwise. 
In order to gain insights to cancer progression, several works analyzed enrichment of functionally related groups of genes 
(gene-sets) under various cancer types such as leukemia, lung cancer, breast cancer and prostate cancer (Segal, et al., 2004; 
Subramanian, et al., 2005; Tomlins, et al., 2007). Gene-sets contain functionally linked genes. These links were curated 
using annotations from the literature such as interacting genes, genes belonging to the same pathway, co-expressed genes in 
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various microarray experiments or genes sharing common regulatory motifs. Several methods were used to identify gene-
sets consistently up or down regulated given a set of conditions (gene expression samples).  For example,  the gene-set 
signature identified by Chinnaiyan and coworkers (Tomlins, et al., 2007) implicated two new genes (ZIC2 and NPAL3) in 
the progression to metastatic prostate cancer from benign epithelium.
Instead  of  relying  on  predefined  gene  annotations,  Rhodes  et  al. (Rhodes,  et  al.,  2005)  created  a  predicted  human 
interactome (whose links were not necessarily physical connections between proteins) and used this network to identify 
groups of  genes  overexpressed  in  pancreatic  adenocarcinoma,  myeloma and  renal  cell  carcinoma.  They combined the 
evidence from independent data sources, such as PPIs (Salwinski, et al., 2004), similarity between gene-expression profiles 
across several human tissue-samples (Rhodes, et al., 2007), domain combinations of known PPIs (Mulder, et al., 2003) or 
shared functional annotations (Harris, et al., 2004). A PPI network was obtained with the integration of these independent 
evidences in a probabilistic framework by means of a naive Bayesian classifier. This PPI network contained proteins as 
nodes and each link had a score with its likelihood. This network helped to implicate  RSU1 as a tumor suppressor in the 
integrin signaling pathway after the experimental validation of the interaction between the genes of RSU1 and LIMS1 (an 
integrin-mediated signaling adaptor protein). Network guided implication of genes in various cancer types is explained in 
the next section (Section 2.4). The subnetworks activated in cancer are further discussed later (see Section 2.5). 
4. Network guided prediction of relevant genes involved in cancer progression
Cancer is a complex phenotype that recruits multiple genes whose products (proteins) tend to physically interact with each 
other(Jonsson and Bates, 2006; Kar, et al., 2009; Wachi, et al., 2005). In the light of the recent findings suggesting that 
proteins rarely act in isolation, the focus of research has shifted towards identifying the set of genes whose products work in 
cooperation. To this end, several methods exploiting guilt-by-association principle have been developed. In the context of 
disease associations, guilt-by-association principle suggests that a gene, whose gene product interacts with the products of 
known disease genes (seed genes), is likely to be a disease gene (Aerts, et al., 2006; Lage, et al., 2007). PPIs are concise 
descriptors  of  relationships  between  proteins  and  the  genes  encoding  them.  For  this  reason,  the  topology of  the  PPI 
networks have been extensively used to associate genes with diseases in the past years. An outline of the methodology of 
associating genes with a phenotype using known associations and PPIs is given in Figure 1.
Early attempts  to  identify  novel  cancer-associated genes  considered only direct  interacting partners  of  known cancer–
associated genes (Aragues, et al., 2008; Ostlund, et al., 2010; Pujana, et al., 2007). Though the local neighborhood (direct 
interaction partners) of genes offers some clues for associating genes with diseases such as cancer, this approach misses the 
remaining information in the global network. Towards extending the amount of information extracted using interactions 
between genes, clustering based methods were also utilized (Milenkovic, et al.,  2010; Navlakha and Kingsford,  2010). 
However,  in  order  to  fully  exploit  network topology,  global  topology based approaches  have been  recently  proposed. 
Several works use shortest paths from known disease-associated genes (Dezso, et al., 2009; Guney and Oliva, 2011; Wu, et 
al., 2008), some use either kernel based diffusion (where more distant nodes have less weight/influence) (Ma, et al., 2007; 
Nitsch, et al., 2010; Qiu, et al., 2010) or message passing (Guney and Oliva, 2011) over the links of the network and some 
others simulate a random walk model on the network (where each node is assigned with the probability of a random surfer 
ending up in the node while surfing through the links of the network) (Chen, et al., 2009; Guney and Oliva, 2011; Vanunu, 
et al.,  2010).  Methods based in global topology, especially the ones based on random walk and message passing, were 
demonstrated to outperform methods based in local topology (Guney and Oliva, 2011; Navlakha and Kingsford, 2010; 
Vanunu, et al., 2010). Several of these methods have been applied on various cancer types, like prostate and breast cancer, 
suggesting novel associations for the implication of genes in specific mechanisms of the disease progression (Chen, et al., 
2009; Qiu, et al., 2010; Vanunu, et al., 2010). In the following text, we explain in detail some of the works that successfully 
identified novel associations for various types of cancers.
For example, with the intention of extending a set of known breast cancer oncogenes (BRCA1, BRCA2, ATM, CHEK2), 
Pujana et al. (Pujana, et al., 2007) used the functional associations of these four genes with other genes and pinpointed those 
which probability to be involved in breast cancer was high. First, they found the genes co-expressed with each one of them 
(assessed by Pearson correlation coefficient). They identified 164 genes commonly co-expressed with all four oncogenes 
(BRCA1, BRCA2, ATM, and CHEK2). Next, they created a functional association network with these 164 genes, covering 
protein-protein interactions from literature, complex memberships, phenotypic similarity, co-expression, genetic interactions 
of orthologous genes and indirect associations (two genes connected by a third one). The genes of this network (consisting 
of 118 genes and 866 functional links) were scored according to GO term enrichment, conservation of co-expression across 
species, co-expression in breast tumor-derived cell lines, expression changes in BRCA1mut in breast tumors and functional 
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similarity with any of the four known oncogenes. This scoring protocol revealed several candidate genes for developing 
breast cancer, among which HMMR was experimentally linked to tumorigenesis and centrosome dysfunction. In a follow-up 
work, Pujana and colleagues (Bonifaci, et al., 2008) took a similar approach to suggest novel candidate-genes for breast 
cancer  through  integration  of  PPIs  with  several  genomic  and  proteomic  data  sources.  These  data  sources  included 
expression  changes  in  tumors  relative  to  normal  tissue  samples  and  copy  number  variations  correlating  with  gene 
expressions. 
In another work, Aragues and coworkers (Aragues, et al., 2008) postulated that integrating PPI and genomics data would 
improve the prediction of cancer-associated genes. They combined several sources of data, such as gene expression, protein-
protein interactions and structural-functional-evolutionary features  (Furney, et  al.,  2006) to  predict  genes  implicated in 
cancer.  A prediction model  was built  based on the  integration of  data (Figure 2).  Genes were associated  with cancer 
provided that i) their products interacted with known cancer genes (retrieved from literature), ii) they were differentially 
expressed in a number of different cancer types, and iii) they shared structural, functional and evolutionary properties with 
known cancer genes. This combined prediction model outperformed each of the single-model predictions and it was used to 
produce a reliable list of cancer gene candidates. 
Similar to the works above, Östlund et al. (Ostlund, et al., 2010) adopted the idea of looking at the network neighborhood of 
known cancer genes to predict novel cancer associations. They curated a set of 812 cancer genes from Cancer Gene Census 
(Futreal, et al., 2004) and text mining on UniProt (Bairoch, et al., 2005) entries. Then, they ranked the genes in a functional 
association network (high confidence links of FunCoup (Alexeyenko and Sonnhammer, 2009)) based on the number of 
cancer-associated genes connected with them. They showed that the higher the ranking of a gene was, the more likely the 
gene was involved in the biological  functions associated with cancer (using GO (Ashburner,  et  al.,  2000)) and it  was 
differentially  expressed  in  cancer  tissues  (using  Human  Protein  Atlas  (Berglund,  et  al.,  2008)).  Among  1891  genes 
connected with at least one known cancer-associated gene, they highlighted 185 genes with 10 or more linked cancer-genes 
and suggested them as candidates for further confirmation. In a slightly different approach, the comparisons between the 
PPI networks of a cancer phenotype and normal tissues were employed by Chu and Chen (Chu and Chen, 2008) to address 
the problem of identification of potential drug targets in human cervical carcinoma. They created condition-dependent PPI 
networks using a nonlinear stochastic model with microarray data to keep or remove the interactions. The interactions were 
distinguished as gain-of-function if they existed in the network of human cervical carcinoma cells but were absent in the 
network of normal primary lung fibroblasts samples.  The interactions were distinguished as loss-of-function otherwise. 
They identified BCL2, caspase-3 and TP53 as potential drug targets.
Guo et al. (Guo, et al., 2007) developed an algorithm to identify the portion of the human interactome that responded to 
different  conditions  such as  pathophenotype or  environmental  change and  then  used this  subnetwork to  predict  novel 
disease associations. The activity score of an edge connecting two nodes (products of genes) was defined as the covariance 
of the gene expression between the two nodes.  An optimally active subnetwork was gradually constructed such that the 
addition of  an edge increased the overall  activity score of  the subnetwork.  They applied this  algorithm to the human 
interactome retrieved from HPRD (Peri, et al., 2004) using an expression data set of 71 prostate tumors and 41 normal 
prostate specimens (Lapointe, et al.,  2004). The prostate-cancer responsive subnetwork contained 2181 nodes and 3200 
edges and covered 74 of 118 prostate-cancer associated genes of the Prostate Gene Database (Li, et al., 2003). Next, a sub-
region was defined with the genes of the subnetwork that interact with known prostate-cancer associated genes. 8 out of 17 
genes were linked with at least two genes associated with prostate-cancer in the sub-region and they were reported to be 
involved in the pathology of pancreas cancer too. The detection of this kind of subnetworks (i.e. active subnetworks whose 
genes change their expression behavior under a certain phenotype) using PPIs and gene expression profiles has been a hot 
topic of research for the last few years (Ideker, et al., 2002; Ulitsky and Shamir, 2007; Ulitsky and Shamir, 2009). In the 
next section, we explain how to use these subnetworks for prognosis.
5. Predicting disease prognosis using dysregulation patterns in networks 
Revealing alterations in cellular pathways in response to cancer is crucial to determine patient prognosis, where tumor cells 
manifest disruptions of the normal gene expressions. With this respect, many studies to identify cancer biomarkers by means 
of the analysis of gene expression patterns exist in the literature (Ludwig and Weinstein, 2005; Sawyers, 2008). However, 
the combined use of network modeling and gene expression data to discover gene-sets capable of distinguishing different 
disease states (e.g., good outcome versus poor outcome) is very recent. These gene-sets can be extracted exclusively using 
regulatory networks (Lim, et al., 2009), but the possibility of using dysregulation patterns in PPI networks to predict a 
disease outcome or prognosis has motivated many researchers during the past decade because of its potential to improve the 
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predictions (Nibbe, et al., 2011) (see Figure 3 for a conceptual overview of these methods). 
Efroni  et  al. (Efroni,  et  al.,  2007)  assessed  the  activity  of  pathways  described in  the literature  (Buetow,  et  al.,  2002; 
Schaefer, 2004) using gene expression data compiled over multiple published studies for various cancer types. They first 
calculated the probability of a gene being in either up or down state in cancer (i. e. showed higher/lower expression in 
cancer  samples  in  comparison  to  normal  samples).  Next,  they  calculated  an  activity  score  for  each  interaction in  the 
pathway by incorporating the probabilities of interacting genes. The overall activity score of a pathway was then computed 
as the average of the activity scores of all interactions. Using a subset of these pathways, selected by a machine-learning 
approach and a Bayesian classifier, they were able to classify the tumor samples with 98% accuracy. Interestingly, the most 
discriminative pathways were  Trka Pathway, DNA Damage pathway, Ceramide Pathway, Telomerase  Pathway,  CD40L 
Pathway and Calcineurin Pathway.
Similarly, Chuang et al. (Chuang, et al., 2007) developed a network-based approach to identify functionally related genes 
distinguishing post-surgery metastasis in breast  cancer patients.  The method associated the phenotypic variance among 
cohorts of patients with clusters of genes. After mapping expression data on the protein interaction network, they identified 
subnetworks  involving  products  of  coherently  expressed  genes.  A score  was  assigned  to  a  candidate  subnetwork  by 
averaging the normalized expression values of its genes using each sample (patient) in two cohorts of metastatic and non-
metastatic breast cancer patients (van de Vijver, et al., 2002; Wang, et al., 2005). Starting from a single seed node in the 
interaction network, a candidate subnetwork was greedily constructed by considering the neighbors of the nodes already 
included in the subnetwork and within a specified distance from the seed. These candidate subnetworks were scored in 
terms of their potential to discriminate between the two cohorts (metastatic and non-metastatic patient groups) using mutual 
information. Their results showed that these subnetworks contained genes playing a central role in connecting differentially 
expressed genes, even though some of these genes were not differentially expressed. They also proved that the genes of 
these subnetworks were better  predictors  of  metastasis  than  markers  based  on single  genes.  This  improvement  of  the 
prediction highlighted the importance of network topology for characterizing genetic elements involved in breast cancer 
metastasis. In a follow-up study by Lee  et al. (Lee, et al., 2009) the same subnetwork identification method was used to 
identify subnetwork dysregulated in acute myeloid leukemia patients. They identified subnetworks that were tightly coupled 
with key leukemogenic processes such as myeloid differentiation, cell signaling of growth and survival, cell cycle and cell 
and tissue remodeling. 
Nibbe et al. (Nibbe, et al., 2009) adapted the subnetwork scoring method of Chuang et al. (Chuang, et al., 2007) to identify 
genes that were discriminative of late stage of human colorectal cancer. Candidate subnetworks were generated by including 
the partners of 67 seed genes associated with colorectal cancer (according to 2D gel experiments). Gene expression data was 
also used to score these subnetworks according to their discriminative power between cancer and control. Several evidences 
were found in the literature supporting the relevant roles of some of the genes of the subnetworks being actively implicated 
in human colorectal  cancer,  such as:  CNSK2A2, PLK1, IGFBP3 (involved in progression),  PDFGRB (with metastatic 
potential), IFITM1 (as a biomarker). This work presents a clear example of the benefits of integrating proteomics, gene 
expression and protein-protein interaction data.
Nibbe  et  al. (Nibbe,  et  al.,  2010)  further  extended  their  approach  by  incorporating  additional  proteomics  and  gene 
expression data as well as a guided search of subnetworks using a guilt-by-association score. A random walk algorithm was 
employed  to  calculate  colorectal  cancer  association  scores  of  genes  in  the  interaction  network,  where  differentially 
expressed genes were used as seeds. The subnetworks included the genes interacting with seed genes (as in previous work 
(Nibbe, et al., 2009)) and those with high association scores. They showed that these subnetworks classified tumor samples 
better than subnetworks that contained only those genes interacting with seeds.
Taylor et al. (Taylor, et al., 2009) investigated rewiring and modularity of the interaction network during tumor progression. 
First, they analyzed an interaction network containing experimental and predicted protein-protein interactions and including 
expression data from 79 human tissues (Su, et al., 2004). The hubs in this network were grouped based on the average of co-
expression with their partners as either inter-modular hubs (co-expression was restricted to specific tissues) or intra-modular 
hubs (co-expressed in most of the tissues). According to their study, the interactome was modular with inter-modular hubs 
connecting modules composed of intra-modular hubs that tend to be functionally more coherent than inter-modular hubs. 
Furthermore, they observed the predisposition of inter-modular hubs to be associated with cancer phenotypes (according to 
the mutations listed in OMIM (McKusick, 2007) and the census of cancer genes (Futreal, et al., 2004)) than intra-modular 
hubs. Using a cohort of sporadic non-familial breast cancer patients (van de Vijver, et al., 2002), they identified 256 hub 
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genes showing significant changes of co-expression between two patient groups classified by survival time (good and poor 
outcome  patient  groups).  These  findings  suggested  that  altered  gene  expression  in  breast  cancer  affected  survival. 
Accordingly, they defined the subnetworks that define the phenotypic variation (i.e. subnetworks active in cancer patients) 
as the hubs whose expression is significantly altered plus the genes interacting with them. They developed a classification 
system  using  relative  expression  within  these  subnetworks  and  affinity-propagation  clustering  algorithm.  They  first 
determined the hubs for which the relative expression differed significantly between patients who survived versus those 
who died from  disease. Next, they clustered the patients using relative expression of these hubs as features. Then, they 
predicted the outcome of the prognosis for a patient based on identified clusters. Their classification achieved 71% area 
under ROC curve (AUC), which increased to 78% when clinical data such as patient age, tumor stage and tumor grade were 
incorporated. The prediction performance of the proposed classification system compared favorably with the commercially 
available genetic breast cancer diagnostics.
The works mentioned above calculated the activity of a subnetwork by either aggregating or subtracting the expression of 
its  genes.  To capture the effects  of  complex forms of  interactions  within subnetworks,  such as  inhibitory interactions, 
several studies (Chowdhury, et al., 2011; Dutkowski and Ideker, 2011) focused on identifying subnetworks consisting of 
genes  exhibiting  combinatorial  expression  patterns.  These  combinatorially  dysregulated  subnetworks  bore  collective 
differential expression of their constituents (e.g. the subnetwork whose genes were not necessarily all up or down regulated 
but in which the particular combination of genes defined the phenotype better). Combinatorially dysregulated subnetworks 
were shown to distinguish different stages of cancer with high accuracy(Chowdhury, et al., 2011). During the search for 
dysregulated subnetworks, Chowdhury et al. (Chowdhury, et al., 2011) employed a heuristic to extend the list, increasing its 
potential to describe a specific phenotype. Gene expression samples were represented in a binary fashion as having either 
high or low expression (e.g., a binary state). The subnetworks were then referred as state functions where the combination 
of genes in the subnetwork was informative of the phenotype. Using a neural network model whose inputs were states of the 
genes in the subnetworks, they classified metastatic colorectal samples from non-metastatic samples with a precision of 
88% and sensitivity of 95% on average. In another work, Dutkowski and Ideker (Dutkowski and Ideker, 2011) tackled the 
problem of identifying combinatorially dysregulated subnetworks that distinguished various classes of samples by adopting 
a  random  forest  approach.  The  algorithm  generated  multiple  decision  trees  using  gene  expression  of  genes  and  the 
interactions of their products in the PPI network. The rules defined by these decision trees were used to classify metastatic 
samples  from non-metastatic  samples  in  breast  cancer  as  in  (Chuang,  et  al.,  2007).  Their  results  also  confirmed  that 
combinatorially dysregulated subnetworks distinguished better the phenotype of the samples than using only coherent gene 
activities. Chen et al. (Chen, et al., 2011) tackled the same problem by constraining the search for subnetworks and adopting 
a Support Vector Machine approach (SVM) to include the interactions of the genes in the feature space. They showed that  
this approach succesfully classified metastatic and non-metastatic breast cancer samples. 
6. Discovery of biological pathways in breast cancer metastases: A network biology perspective
Breast cancer in women is one of the most common forms of cancer in Europe, around 400,000 cases of breast cancer are 
diagnosed annually (Ferlay, et al., 2010) and the observed incidence of this cancer is expected to continue rising. Although 
there have been great improvements in early detection and treatment, around 30% of early stage breast cancer patients 
experience  recurrent  disease.   Following the  diagnosis  and  initial  surgery to  remove the primary tumor,  patients  may 
experience relapse due to the invasion of distant organs by secondary tumors. A major factor affecting survival in these 
cases is resistance to chemotherapy used to treat primary and secondary tumors. 
In patients with controlled local  cancer,  systemic progression constitutes a major public health problem (Gluck, 2007). 
Breast tumours show an organ-specific pattern in metastasis formation, in which bone (60%), lung (34 %) liver (20%) and 
brain (15%) are the most commonly affected organs (Lu and Kang, 2007). The patterns of metastatic spread vary from 
patient to patient. Some patients may escape relapse entirely. Others develop bone metastases only and may survive for ten 
years or more following the diagnosis. However, the patients who develop metastases in the various visceral tissues have a 
much increased mortality rate and shortened life expectancy. There is a need for research to integrate scientific and clinical 
investigation to understand the basic processes of breast cancer metastasis and translate such insights into clinical care as 
rapidly as possible.
The seed-and-soil hypothesis proposed by Paget (Paget, 1889) in the 19th century postulated that the development of distant 
metastases in cancer patients was dependent both on the characteristics of the cancer cells and the cooperation of the cells in 
the host organ (Fidler, 2003). Breast cancer cell signaling networks are complex systems that integrate information from the 
cellular environment (Manning and Cantley,  2007).  Indeed, metastasis is a complex disease that  involves a number of 
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simultaneous molecular processes (Hortobagyi, 2000; Kaal, et al., 2005; Minn, et al., 2005). The mechanisms that mediate 
organ-specific  pathogenesis  of  metastases  are  the combination of  modifications  that  occur in  both primary  tumor and 
metastatic cells, during the process of spread and microenvironment adaptation (Waltregny, et al., 2000).  
Results  of transcriptomic analysis of cell  lines with specific organ-tropisms indicate the existence of an organ-specific 
metastatic phenotype (Kang, et al., 2003). Among the different studies for organ-specific signatures, there is a significant 
lack of overlap in the selected genes, indicating perhaps a strong platform-dependence or other bias in each study. Also, 
transcriptomic studies on cell lines do not take account of in situ gene expression, and provide information only from the 
cancer cell itself, when it is known that interactions with host cells are also critical for the establishment of metastases. 
Computational approaches are needed to elucidate the regulatory properties of signaling networks of metastasis (Aldridge, 
et al., 2006; Bhalla, 2003; Justman, et al., 2009). Microarray-based gene studies are difficult to interpret, because of the 
huge amount of data involved, and it is therefore a challenge to describe biological insights. Maps of complex networks 
were derived by interconnecting the individual pathways obtained from experimental data (Bhalla and Iyengar, 1999; Weng, 
et al., 1999). These studies revealed that signaling networks contain numerous features, such as feedback and feed forward 
loops (Alon, 2007; Ma'ayan, et al., 2005), which render it virtually impossible for the human mind to decipher how signals 
are integrated within the pathways determining the pathogenic function.  
Large-scale computational comparisons of alterations in thousands of genes and proteins in cancer cells documented in 
inter-laboratory data  are essential  to  identify  key  genes  and/or  proteins  that  are deregulated  in  metastatic  cancer  cells 
(Nguyen and Massague, 2007; Shedden, et al., 2008).  Despite the wealth of molecular profiling data that describe breast 
tumours, our understanding of the fundamental genetic dependences in metastatic progression is relatively poor (Schlabach, 
et al., 2008). Indeed, molecular classification provides insights into breast cancer taxonomy, but its clinical implementation 
is hindered by the unreliability of single sample allocations (Weigelt, et al.,  2010). To design an appropriate course of 
treatment, there is a need for comprehensive functional viability profiles to identify the risk of metastasis and develop 
therapeutic targets.
As mentioned above, a strategy based on mapping expression profiles with protein interactions was described by Chuang et 
al., 2007 (Chuang, et al., 2007). The authors showed that it was possible to extract relevant biological information about 
deregulated functions and the relationship between them, and to identify molecules that could be helpful  as metastatic 
markers or therapeutic targets. The use of a PPI network-based approach identified markers not as individual genes but as 
subnetworks extracted from PPI network,  providing a systemic view of the interactome (Grimaldi,  et  al.,  2009).  This 
method served to filter information by picking out key protein functions as metastasis markers. Thus, PPI network-based 
approach was useful to decipher distinctive phenotypes, since differences between PPI networks revealed characteristic 
traits of each metastasis (Figure 4). 
Coupling microarray data from clinical metastases and immunohistochemistry, Sanz  et al. (Sanz, et al.,  2007) assessed 
association of proteins in the soft-tissue metastases of breast cancer tumors such as liver and lung metastases. They created 
protein interaction networks starting from sets of differentially expressed genes for each phenotype. Next, they analyzed the 
interaction networks to investigate the commonalities between the three soft-tissue human breast cancer metastases and 
showed that although the studied soft-tissue metastases are phenotypically diverse, several metastatic competency genes are 
shared among these metastases. These resemblances in the PPI networks reflected redundant phenotypes in metastatic cells 
that could be useful to colonize several tissues. By this approach, the chaperone GRP75 was found to be only up-regulated 
in liver metastasis, and this discovery was validated in tissue patients. So, this protein could play an important role in the 
pathogenesis of liver metastasis. Furthermore, they revealed the link between HSP60, a widely recognized mitochondrial 
chaperone machine, and BAG2 in both soft tissue metastases. 
In a following study by Martin et al. (Martin, et al., 2008), 18 proteins identified by protein expression difference in brain 
metastasis of primary breast cancer tumors were placed into a network context where associations between proteins were 
defined by protein-protein interactions,  functional  associations from STRING (von Mering, et  al.,  2003) and predicted 
protein-protein interactions using structural similarities or interology. Next, they clustered the extended neighborhood of 
these initial proteins using functions defined in UniProt (Apweiler, et al., 2004) to characterize functional phenotypes that 
could enhance brain metastasis  in breast  cancer  cells.  Their  analysis identified  HSP27,  an ATP-independent  molecular 
chaperone influencing the assembly, transport  and folding of  other  proteins,  as  a  gene implicated in  the pathology of 
metastasis. A similar approach was taken by Sanz-Pamplona  et al. (Sanz-Pamplona, et al., 2011) to discriminate patients 
developing brain metastasis from those who didn’t. Based on a functional study in which the PPI network was divided into 
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modules  of  interacting  proteins  sharing  a  common  function,  they  hypothesized  that  brain  metastasis  cells  had  a 
characteristic behavior named “endoplasmic reticulum stress resistance phenotype”. They further validated the expression of 
proteins in primary breast carcinoma, using both samples that developed brain metastasis and the samples that did not, and 
the search for a multivariate panel of markers revealed the expression of proteins in breast tumors predicting the metastasis 
in  brain.  Indeed,  GRP94,  FN14 and  inhibin was  the  best  combination  to  discriminate  metastasis  samples  from  non-
metastasis samples, achieving 85% of the area under ROC curve.
Moreover,  proteins  from the  family  of  chaperones  and  GRP (Glucose  Regulated  Proteins)  act  as  central  hubs  in  all 
metastasis  networks.  These proteins  have an active  role  in  the  maintenance of  networks architecture,  acting as  a  key 
regulator of cellular systems and working as bridge nodes, binding functional modules of proteins with each other. In the 
case of environmental stress, the chaperones remodel interactions between these functional modules helping the cell to 
survive in a hostile environment (Korcsmaros, et al., 2007; Palotai, et al., 2008).
The developments in therapy are now driving a demand for a more precise prognosis, especially with respect to metastasis. 
The arrival of low toxicity adjuvant chemotherapy has encouraged the identification of breast cancer patients who are at 
high risk of aggressive cancer. Also, the ongoing development of a range of preventative strategies for metastasis formation 
has increased the demand for effective classification of patients who are at increased risk of specific metastasis. 
7. Future directions: From networks to systems medicine
Macromolecular assemblies carry out most biological processes. The interactions between these macromolecules constitute 
pathways, which are networks usually involving transient interactions. Since most of these pathways are interconnected, 
even slightest changes in one pathway can cause abnormal regulation events affecting other biological processes. Taken 
together with the fact that cancer is a disease of pathways rather than single genes, small perturbations hinder the discovery 
of novel drugs causing them to fail at the very last (clinical) phases. Therefore, network medicine approaches aim to foresee 
the outcome of such perturbations in regulation patterns by incorporating protein-protein interactions in addition to the 
available data, helping to define a dynamic context (i.e. proteomic, genomic, metabolic, physiological and environmental 
information) and possibly suggesting points of action (see (Pujol, et al., 2010) and (Fliri, et al., 2010) for reviews). These 
approaches to human disease can have multiple biological and clinical applications: first, they may lead to the identification 
of disease genes and disease pathways; second, they can be applied in the discovery of new targets and development of new 
drugs;  and  third,  some  of  the  new  targets  can  be  used  as  more  accurate  cancer  biomarkers  or  applied  for  a  better 
classification of cancer, improving personalized therapies and treatment (Barabasi, et al., 2011).
In order to tackle with the complexity of polygenic diseases, recently emerged polypharmacological approaches (Hopkins, 
2008) that typically target many proteins simultaneously via the administration of multiple drugs. Such strategies bear a 
potential to intervene the disease progression mechanism by creating a synergistic (more-than-additive) response and to 
reduce the likelihood of drug-resistance by eliminating compensatory reactions (Csermely, et al., 2005). The applicability of 
therapies involving multiple targets was demonstrated for several pathophenotypes such as AIDS or cancer, where optimal 
drug  combinations  were  proposed  (Vazquez,  2009;  Yang,  et  al.,  2008).  In  the  near  future,  however,  network  based 
approaches are expected to prove particularly useful in predicting toxicology and repurposing drugs with secondary targets 
involved in several pathways that are not apparently related to each other.
Another important direction towards effective treatment of cancer is developing DNA-damaging agents that are only toxic 
for the proliferating cancer cells without affecting normal tissue cells. Genetic interactions provide a theoretical framework 
for  identifying  candidate  genes  that  are  synthetic  lethal  (combination  of  two phenotypes  results  in  lethality)  with the 
mutations  causative  of  cancer  (Michod and  Widmann,  2007).  This  kind  of  “next-generation”  approach  might  replace 
conventional methods, such as aggressive drugs and chemotherapy, that damage cancer cells as well as normal tissue cells. 
Although initial studies have reported promising results, where several genes that show synthetic lethality with a handful of 
oncogenes are identified (Luo, et  al.,  2009; Scholl,  et  al.,  2009),  research in this area is  still  in its  infancy. It  can be 
postulated that integration of genetic interactions (such as in (Bandyopadhyay, et al., 2008) and  (Ulitsky, et al., 2008)) will 
play an essential role in building up clinical applications of such next-generation approaches. 
 In conclusion, evaluating the genes and their relationships within the context  of the network –in particular using PPI 
networks– has made possible a better understanding of disease states. Still, even if the results extracted from the works 
mentioned in this chapter are very promising, more research towards delineating network-centric view of cellular processes 
is required to further develop more effective and possibly more personalized therapeutics.
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Figure legends
Figure 1. Network-biology approach to cancer. First step in network-based cancer studies is data integration. (A) Known 
genetic descriptors (such as differentially expressed genes, mutations, etc.) for a given cancer type is either retrieved from 
the literature or experimentally identified. (B) An interactome is constructed using known PPIs. (C) Next, the gene-cancer 
associations obtained in (A) are overlaid on the products of these genes in the interaction network. (D) The phenotypic 
relevances (the likelihood of being involved in cancer) of the genes are ranked based on the topological characteristics of 
their products in the interaction network. (E) Promising candidates (top ranked genes) are computationally validated (e.g., 
by investigating the functional processes they are involved, co-expression with known genes associated with cancer and the 
tissues their products are localized). (F) The predictions are validated in wet-lab and depending on the results of the clinical 
trials (G) the predicted genes become a part of cancer therapies either as targets of drugs or biomarkers distinguishing the 
phenotype.
Figure 2. Combining topological properties of genes with structural and functional features to predict cancer gene 
candidates. (A) The method overview of (Aragues, et al., 2008). First, interactions of known cancer genes are fetched and 
cancer linkage degree is calculated. Second, gene expression from different cancer types is incorporated. Third, genes in the 
network are assigned probabilities based on their structural, functional and evolutionary properties. Finally, cancer genes are 
predicted for each cancer type. (B) Cancer linkage degree of a protein is the number of interaction partners that are known 
to be involved in cancer.  (C) Positive predictive values (the percentages  inside the diagrams) obtained when different 
strategies are applied separately or in combination with others to predict cancer gene candidates. Integration of multiple 
sources of data produced better predictions than the use of one single criterion. For example, combining the cancer linker 
degree with differential expression data increased the ratio of known cancer genes among all predictions from 17% to 73%. 
The figure is adopted from BMC Bioinformatics 2008, 9:172.
Figure  3.  Identification  of  subnetworks  discriminating  cancer phenotype.  (A)  Gene  expression  and  PPI  data  are 
integrated  describing the dysregulation patterns  as  a  result  of  certain  cancer  phenotype.  (B)  Possible  subnetworks are 
searched typically starting from one node and then extending that  node using several  heuristics.  (C) The subnetworks 
combinatorial expression of whose genes discriminate the cancer samples from normal samples are selected for further 
validation.
Figure 4. Deciphering distinctive organ-specific phenotype of breast cancer metastases. Based in comparative protein 
or gene expression analyses between primary tumor and each metastasis location, PPI networks can distinguish organ-
specific preponderant functions. Coupling proteomic, transcriptomic and interactomic data, organ-specific PPI networks are 
reconstructed. The analysis of the networks reveals that although all metastases share common modules (represented in 
orange), each location trigger characteristic pathways and functions showed in red (brain), yellow (bone), green (liver) and 
blue (lung). Moreover, modules can be shared by several metastases according their cellular dissemination or colonization 
characteristics. Gray nodes represent proteins activated in both liver and lung metastases, indicating that important functions 
can be shared by soft-tissue metastases. Bone and brain have a tissular idiosyncrasy and metastasis in these organs derivate 
in a more specific and particular selection process.
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BOX1: Data integration in cancer studies
Over the past years a vast amount of data from experimental cancer studies has been accumulated. Gene expression data is 
publicly available in two major repositories: Gene Expression Omnibus (GEO) (Barrett and Edgar, 2006) and ArrayExpress 
(Parkinson, et al., 2011). These two repositories contain high-throughput functional genomics data, including experiments 
related to different types of cancer (as of September 2011, a simple keyword search “cancer” restricting the organism to 
“Homo sapiens” results  in  102,446 and 211,544  samples  among 624,249 and 691,128 samples  available in  GEO and 
ArrayExpress respectively). In addition to these repositories, several databases such as Gene Expression Atlas (Kapushesky, 
et al., 2010) and Intogen (Gundem, et al., 2010) provide a platform for assessing importance of genes decided by statistical 
analysis  on the  integrated  cancer  expression data.  Oncomine  (Rhodes,  et  al.,  2007) is  another  effort  to  compile  gene 
expression  data  though access  to  advanced features  requires  a  professional  subscription.  Moreover,  initiatives  such as 
International Cancer Genome Consortium (Hudson, et al., 2010), Cancer Genome Atlas (Collins and Barker, 2007) and 
Cancer Genome Project (Dickson, 1999) gather data to define the genetic landscape of various cancer phenotypes, improve 
the data quality and extend the catalog of genetic mutations in cancer. 
 Integrating molecular expression data is crucial to capture condition and time dependent behavior of genes in vivo. On the 
other hand, protein-protein interaction networks provide a snapshot of the relationships between the main actors in the cell. 
Unlike  genomics  data,  the  experimental  data  on  relationships  between  biological  macromolecules  such  as  genes  and 
proteins are spread across  various  data repositories.  BIND(Alfarano,  et  al.,  2005),  BioGRID (Stark,  et  al.,  2011),  DIP 
(Salwinski, et al., 2004), HPID (Han, et al., 2004), HPRD (Keshava Prasad, et al., 2009), IntAct (Kerrien, et al., 2012), 
MINT (Licata, et al., 2012) , MIPS (Licata, et al., 2012), Mpact (Guldener, et al., 2006)  are among widely used publicly 
available protein interaction databases. Furthermore, most of these databases lack a standard nomenclature and interface for 
the data they provide. To facilitate inter-operability among these databases, several software tools have been developed. 
These tools use equivalent  identifiers  or  common features  from different  repositories  (e.g.  sequence identity or  cross-
reference identifiers) to merge data. A list of available biological data integration tools are given in Table 1. Some of these 
tools allow users to merge their own data with other available biological data to fetch species-wide genomic, proteomic and 
metabolomic  annotation  spread  across  various  repositories  such  as  UniProt  (The-Uniprot-Consortium,  2011),  KEGG 
(Kanehisa, et al., 2012), Reactome (Croft, et al., 2011) and major interaction data resources listed above.
BOX2: Basic concepts in graph theory
Relationships between discrete biological molecules (e.g. transcipts, proteins, metabolites) are typically represented as a 
network. Definitions and algorithms in graph theory provides a theoretical framework to characterize such networks. A 
graph (network) G = (V, E) is formally defined on a set of vertices (nodes) V and set of edges (links) E connecting a subset 
of V. G is called as a directed graph if its edges imply a directionality between the nodes they are connecting such that for 
two nodes u, v there are two possible edges: from u to v, (u,v); and from v to u, (v, u). In an undirected graph however, the 
edges between two nodes have no orientation. The  degree of a node is the number of edges that connect to it and the 
vertices connected by these edges are called the neighbors of the node. Nodes with higher degrees are defined as hubs. The 
actual value of the degree threshold for defining a hub varies from study to study and depends on the biological context that 
the network represents. The shortest path between two nodes is the path in the network such that the sum of the weights of 
its constituent edges is minimum, thus there may be more than one shortest path connecting two nodes. The length of the 
shortest path between two nodes is called as the distance between these two nodes. G is a connected graph if there is a 
path between every pair of nodes in G. A subset S of the vertices V induces a subgraph (subnetwork), whose edges are a 
subset of E, that are the edges that connect two vertices inside S. All the connected subgraphs of G are called connected 
components of G. Centrality of a node in G determines the relative importance of that node within the graph and can be 
assessed  using  various  metrics  such  as  degree  centrality,  closeness  centrality,  betweenness  centrality  and  eigenvector 
centrality. A clique is a special type of subgraph where each node is connected with all other node and a clique with k nodes 
is referred as k-clique. The clustering coefficient of a node is the ratio of the number of the edges connecting any pair of its 
neighbors to the number of all possible edges that would exist between all possible pairs of neighbors. The degeneracy of G 
(k-core), the measure of how sparse G is, is given by the smallest value of k where in every possible subgraph of G, a node 
has a degree of at most k. The k-core of G is obtained by successively removing nodes with degrees less than k to the point 
that no further node removal is possible.
BOX3: Evaluating classifier performance
The prediction performance of a classifier is typically assessed with several metrics based on the number of true positives 
(“good” instances predicted as good),  true negatives (“bad” instances predicted as bad),  false negatives (good instances 
predicted as bad), false positives (bad instances predicted as good). Accuracy is the fraction of all correct predictions (true 
positives  and  true negatives)  among all  predictions.  Precision is  the  ratio  of  true  positives  to  true positive plus  false 
positives (fraction of correct predictions for good instances among all predictions saying an instance is good). Sensitivity is 
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the ratio of true positives to true positives plus false negatives (fraction of correct predictions for good instances among all  
good instances). Specificity is the ratio of true negatives to true negatives plus false positives (fraction of correct predictions 
for bad instances among all bad instances). A ROC (receiver operating characteristic) curve compares sensitivity versus (1-
specificity) while the threshold for being true positive is varied. The AUC (area under ROC curve) equals to the probability 
that a classifier will rank a randomly chosen true positive higher than a randomly chosen true negative. The practice of 
splitting the data into n groups and using (n-1) of these groups for training purposes while keeping the remaining group for 
testing is called n-fold cross-validation. During n-fold cross-validation, the process of choosing the groups are repeated n 
times such that each group is used once as the training set. This practice helps reducing the bias of the predictor towards the 
initial data used. 
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Table 1. Comparison of biological information integration software. *
Feature BI PI PN AP BN UH MI ON iRI
Data types
Supports multiple biomolecule types (protein, 
gene, compound...) • •  • •
Supports multiple relation types (interaction, 
complex, pathway...) •   • • • •
Supports multiple data descriptor/identifiers types • • • • • •  • •
User extensible to new user defined data types 
and attributes •      
Data 
Unification
User specific data unification •      •
Standard user can extend to new data 
repositories •      •
User 
Interface
Standalone Graphical Interface   •   •
Scripting / Command line • •  •   •
Provides a webserver •  • • • • • •
Provides a plugin for Cytoscape •  •   • •
Network 
analysis
Adds network analysis methods • • •  •   •
Availability Open Source • •  •   •
Installatio
n
Does not require additional software • • • • • •
Standalone application (runs locally) • •  •   •
* Table adopted from Garcia-Garcia et al. (Garcia-Garcia, et al., 2010). Abbreviations: BIANA (BI); PIANA (PI); 














A novel network-based disease-gene prioritization frame-
work
In this thesis, I have presented a novel disease-gene prioritization framework, GUILD,
which associated genes with diseases using the global topology of the network and an
initial set of genes known to be implicated in the disease. Three algorithms have been
designed and implemented in GUILD: NetScore, NetZcore, NetShort. These methods
assigned a disease-association score to each node in the network considering the prox-
imity to the known disease-gene associations (seeds).
In each case, the algorithms captured different aspects of the network topology by
defining proximity in a different way. NetScore not only checked the shortest paths
between nodes for calculating the distance in-between but also accounted for multiple
shortest paths between nodes. NetZcore evaluated the proximity as the number of neigh-
boring nodes but the adjacency is further refined to represent the biological significance
of the neighborhood using an ensemble of networks in which nodes were shuffled ran-
domly preserving the topology of the original network. The proximity in NetShort was
assessed by the number of seeds contained in a path. These algorithms were combined
in NetCombo, an algorithm which calculated average of the normalized scores coming
from all three algorithms above.
In addition to these algorithms, four existing network-based prioritization algo-
rithms, Functional Flow [Nabieva et al., 2005], PageRank with priors [Chen et al.,
2009], Random walk with restart [Kohler et al., 2008] and Network propagation [Va-
nunu et al., 2010] have been implemented in GUILD (among the existing algorithms,
only PageRank with priors algorithm had a publicly available implementation). GUILD
was made publicly available as a standalone software package at sbi.imim.es/
GUILD.php. A manual providing instructions on how to install and use the software,
along with example input files was also provided.
Benchmarking network-centric guilt-by-association
The prediction capacity of the network-based prioritization methods in GUILD was
tested throughly at genome-wide scale using disease-gene annotations from various
datasets (such as OMIM, GAD, CTD and several available as expert curated datasets)
covering around 100 different disease phenotypes and PPI networks (human interac-
tomes at different levels of granularity integrated from several major PPI databases).
On average NetCombo, the consensus method combining the results of NetScore, NetZ-
core and NetShort, outperformed state-of-the-art network-based prioritization methods
included in GUILD.
The results suggested that NetCombo and NetScore exploited the global topology of
the network better than the existing methods. Typically, available network-based prior-
itization methods consider all the paths between nodes equally relevant for a particular
disease. In this regard, incorporating a refined definition of closeness while assessing
the relevance of the nodes in the network improved the prediction accuracy.
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Some of the prioritization algorithms, NetScore, NetZcore and Functional Flow re-
quired a user-defined parameter: the number of look-ahead links during the proximity
calculation in the network. That is, how many links further from one node should the
algorithm consider. A value of 6 in the case of NetScore and 5 in the case of NetZcore
and Functional Flow have been found to be optimum during the parameter optimization
process. Given that PPI networks have been found to be scale-free and bear ”ultra-small
world” effect (one can reach to any node with much less than 6 links), these values co-
incided with the expectation that the nodes further than 5− 6 links did not provide any
information that would improve the annotation.
Several of the existing methods like PageRank with priors and Random walk with
restart have addressed genome-wide disease-gene prioritization previously [Wu et al.,
2008, Navlakha and Kingsford, 2010], however a comprehensive comparison of network-
based prioritization methods using only network topology has not been available so far,
probably due to two main reasons. First, most of these methods are either not avail-
able as a standalone tool or accessible through interfaces with limited functionality (i.e.
as a web server [Kohler et al., 2008, Chen et al., 2009] or Cytoscape plugin [Gottlieb
et al., 2011]). Second, these methods integrate a variety of additional data including
phenotypic similarity between diseases. Furthermore, most of the candidate disease-
gene prioritization studies focus on the prioritization of genes within the genetic linkage
interval of a given disease-gene. The prediction performance of the method is then eval-
uated based on whether it could rank the disease-gene highest among the 100 closest
genes (to the disease-gene) in the linkage interval. However, considering 100 closest
genes as candidates could be too restrictive in some cases, since the linkage interval
might contain as many as thousands of genes and multiple disease-genes can fall un-
der the same genetic interval. Therefore, the prioritization methods were benchmarked
assuming all the genes (whose products are in the interaction network) as candidates.
To ensure a fair evaluation, the negative genes were selected in two different ways: i)
assuming all non disease-genes as negatives (not associated with the disease) and ii) as-
suming a balanced distribution between disease-genes and non disease-genes (achieved
by grouping non disease-genes such that there were equal number of disease-genes and
non disease-genes).
Biological significance of the predictions
The network-based algorithms assigned a ”proximity” score for each node in the net-
work corresponding to the likelihood of that node being involved in the phenotype of in-
terest. The nodes were then ranked/prioritized with respect to the calculated score. The
validity of these scores was confirmed on disease-gene associations provided by CTD.
The NetCombo scores calculated for Alzheimer’s disease (AD), diabetes and AIDS,
distinguished disease associated genes from genes that were not associated with the
disease (no-association genes). The findings also demonstrated that there were 4 to 8
times more disease-genes than no-association genes at a reasonable score cutoff (e.g.,
0.1 within the range of [0, 1]).
The analysis of top-ranking genes (i.e. genes encoding highest scoring 1% of the
nodes) further proved the utility of the prioritization using NetCombo. For all of the
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three disease phenotypes, top-ranking genes covered significantly more disease genes
with respect to GAD. Among these three phenotypes, prioritization yielded slightly
poorer results in diabetes which could be due to the definition of the diabetes phenotype
merging diabetes type 1 and 2 in a single phenotype.
When the biological processes enriched among the top-ranking genes were taken
into account, Notch and amyloid pathways stood out in AD and inflammatory response
pathway was implicated in diabetes and AIDS. Moreover, in the case of AD, some
of the predictions were consistent with the literature and network-based prioritization
highlighted several genes that have recently been implicated with the disease pathology.
It is also worth mentioning that some of these genes did not fall to any known linkage
interval for AD pointing out the potential of genome-wide prioritization.
Dependence on current knowledge
Two main components of the network-based prioritization are the information on the
seeds and the network through which the information of the seeds is transferred to the
other nodes. Just as the way that there is no guilt if there is no proper evidence, the
success of the prioritization would be dependent on the quality of seed and PPI infor-
mation.
As the size of the PPI network went up, the prediction accuracy of the network-
based prioritization methods increased with the exception of the interaction network
which contained protein complexes in addition to binary (physical) interaction informa-
tion. This finding was not surprising considering that the more was known on the rela-
tionships between genes (or their proteins) the more accurate would be the annotation.
However, protein complexes might be introducing spurious interactions. Take a com-
plex consisting of three proteins A, B and C for example. The interaction between A-B
and B-C may exist while A and C need not necessarily be interacting with each other.
Although complex involvement could be thought as functionally and thus phenotypi-
cally informative, it is not as informative as physical interaction and may hinder precise
functional characterization. Another key finding arose from testing various types of PPI
networks was that incorporating additional evidence for the functional importance of
the interaction (e.g., genomics data relating two genes connected in the network) could
further improve the prediction performance of the prioritization.
On the other side, the prediction capacity of the prioritization methods varied sub-
stantially over different disease phenotypes. The prioritization methods worked better
on several diseases (i.e., OMIM disorders merged with respect to the first keyword)
such as amyloidosis, myasthenic, myocardial and xeroderma whereas for mitochon-
drial, osteopetrosis and epilepsy they were less successful. The number of seeds in each
disease was quite diverse, nevertheless, there was no correlation between the prediction
accuracy and the number of seeds given for the disease. Rather surprisingly, several pri-
oritization methods, including NetCombo achieved better performance for diseases with
lower number of seeds. Nevertheless, the topology of the network was observed to play
a more important role than the number of seeds in defining the outcome of the priori-
tization. In general, the prioritization performance was slightly higher for the diseases
whose seeds were connected to each other with shorter paths.
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Using a dataset in which the phenotype is defined in a broader sense (the dataset of
[Goh et al., 2007]) such that the disease-gene associations of a number of phenotypes
are grouped together allowed to evaluate the effect of the quality of the known disease-
gene associations. The prediction performance were lower in this dataset compared to
other disease-gene association datasets tested.
Robustness and fragility
Robustness of five of the network-based disease-gene prioritization algorithms men-
tioned above (NetScore, NetZcore, NetShort, Functional Flow, PageRank with priors)
were further analyzed using randomly perturbed seed sets and PPI networks for a subset
of diseases. As expected, for all the methods, the prediction capacity fell down linearly
as the noise in the seed set increased. Consistent with the findings mentioned above,
the quality of the seeds affected the outcome of the prioritization more than the number
of seeds. A relevant implication of this finding for guilt-by-association approaches in
general is that one should use a grain of salt while incorporating data that is not expert
curated, as this may be worsening the power of the method rather than improving.
When the noise was introduced in the network via rewiring interactions, the predic-
tions were also less accurate, though the pace of the drop in the accuracy with respect
to the amount of perturbation introduced was rather slow compared to the drop in the
accuracy due to the perturbation of the seeds. Moreover, the prediction performance of
PageRank with priors method was less effected compared to the rest despite rewiring
meaning that the probability of randomly reaching to a node over the links of the net-
work remained similar. This might have emerged from the scale-free nature of the PPI
network, where proteins are connected with each other with very short paths. Thus,
rewiring interactions preserved considerably the probability of reaching from one node
to another.
On the other hand, a rather unexpected behavior was observed with random removal
of interactions in the network. The prediction performance of NetScore, Functional
Flow and PageRank with priors went down as the interactions were deleted from the
network, whereas, NetZcore and NetShort increased their prediciton performance with
less number of interactions. Strikingly NetZcore and NetShort were able to predict
disease-genes better than random even when half of the interactions in the network
were removed.
This observation could be explained by the two aspects of network-based prioritiza-
tion: first, the data underlying the prioritization and second, the way these two methods
worked algorithmically. Firstly, the seeds were a tiny portion (typically much less than
1%) of all the genes in the network so were the interactions connecting a seed with
another seed or any other node among all the interactions in the network. Therefore,
the probability of removing an edge connecting two seed or a seed and non-seed was
lower compared to the probability of removing an edge connecting two non-seeds. That
would suggest that the perturbed networks would be more likely to preserve connections
among seeds. Indeed, a case study on AD supported this explanation where the ratio of
AD-related genes in the neighborhood increased as the interactions were removed.
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Secondly, turning to the algorithmic properties of the prioritization methods, Net-
Short gave more weight to the paths containing more seeds. A performance improve-
ment implied that random interaction removal eliminated paths with less number of
seeds (since it was more likely to remove an edge connecting non-seeds). A similar
rationale applied to NetZcore, which boosted the score of the node based on the num-
ber of neighboring seeds in the original network compared to the random ensemble of
networks. Seed-seed connections were more likely to be preserved with random edge
removal in the original network and thus would become more significant compared to
the random ensemble of networks. With the same line of reasoning, the performance
drop observed in NetScore, the method that considered all possible shortest paths be-
tween nodes, provided evidence for the existence of alternative routes between seeds.
In other words, although removing interactions was more likely to eliminate non-seed
connecting paths, the predicton accuracy of NetScore went down since alternative short-
est paths connecting seeds –which possibly included non-seed connections in-between–
were affected.
Taken together, these results suggested that disease phenotypes reflect the robustness
of the underlying biological systems. The cell can maintain its functioning to a certain
extent even under abnormal conditions and this is likely to be valid for disease states.
Moreover, redundancy, that is the existence of backup circuits within the interaction
network played a key role in robustness. Nevertheless, this does not mean that the bio-
logical system is immune to all kind of perturbations. Certain specialized perturbations
can easily exploit the fragility of the system. In particular, under the context of diseases,
the information of seeds and the connections between them could substantially affect
the prioritization of disease-genes constituting the Achilles’ heel of the network-based
prioritization. Still, it should be taken into account that the analysis presented here is a
rather indirect way of proving robustness involving both the disease state and the under-
lying biological system and further investigation (e.g., testing nodes that change seed
connectivity most for the association to the disease) is required to biologically support
these findings.
Identifying functional decoupling and its implications on
the plasticity
The analysis of the prioritization methods with respect to their ability to identify groups
of genes functionally related to the disease showed that NetScore was superior to the
rest of the methods. The genes prioritized by NetScore tended to cluster in the network
as connected set of genes and these clusters were more enriched in those GO functions
that were enriched among the seeds. This method was then used to check whether there
were certain features of diseases mediating the outcome of the prioritization with the
hypothesis that it might be easier to recover the disease-genes for a particular group of
diseases. It was assumed that investigating the capacity of the network-based prioritiza-
tion to recover disease-genes under perturbed conditions would delineate the adaptation
capacity of the disease to the changing environment (e.g., drugs attacking to certain
PPIs).
Overall prediction accuracy and being able to distinguish between groups of con-
nected genes with functions identical to those of the seeds were two key criteria to
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choose the prioritization method for investigating disease-mediated features. NetZcore
also satisfied these criteria however, as mentioned above, it proved intrinsically more
robust against the perturbations on the seeds and the network. Thus, the observed per-
formance would be more likely to account for the robustness of the method in addition
to any disease-mediated feature. To minimize the bias that might be introduced by the
method NetScore was chosen instead.
Based on the performance of NetScore prioritization over perturbed networks, the
diseases were grouped into two main categories: diseases whose associations were eas-
ier to recover using network-based prioritization (robust) and those that were harder
(non-robust). Interestingly, robust diseases were more likely to include diseases with
high prevalence in society including breast cancer, diabetes and obesity. Robust dis-
eases were distinguished from non-robust diseases by the connectedness of their seeds
in the network. A disease was more likely to be robust if its seeds were connected
with shorter paths to each other. The top-ranking genes of the robust diseases showed
slightly increased modularity compared to the top-ranking genes of the non-robust dis-
eases. Moreover, both the seeds and the top-ranking clusters of the robust diseases
tended to cover a larger number of biological functions than non-robust diseases.
These findings pointed out two other aspects of robustness: functional decoupling
and functional diversity. The biological processes relevant for the diseases are handled
through designated units (modules) diverse in function and the modularization is proba-
bly achieved by having shorter connections between disease-genes at the network level.
Consequently, the network-based prioritization method recovered the mediators of the
phenotype (disease-genes) easier in spite of perturbations in the underlying network for
the diseases whose seeds were more connected in the network. Therefore, it is claimed
that these diseases would be more likely to show plasticity and adopt to changing con-
ditions than the rest of the diseases. The reason why polypharmacological approaches
targeting multiple gene products simultaneously work better on the diseases such as
AIDS or cancer might be due to such plasticity these diseases may have.
Extending the focus to non-disease phenotypes
Though mainly tested on disease phenotypes, the network-based prioritization meth-
ods presented in this thesis can be applied to any phenotype given a set of phenotypic
annotations (seeds, e.g., disease-genes in the case of diseases) to be transferred over
the network. Nonetheless, a common challenge in phenotypic characterization using
guilt-by-association principle is often the lack of such phenotypic annotations.
This challenge has been addressed by integrating phenotype-gene information from
various available biological data repositories such as UniProt, GO and OMIM and by
applying network-based prioritization method in order to characterize genes for their
relevance to any given phenotype. GUILDify, a free and easy to use web server has
been made publicly available at sbi.imim.es/GUILDify.php.
GUILDify locates phenotype-gene annotations by searching for the user-provided
keywords in its knowledge base and provides a genome-wide ranking for all genes in
the PPI network. The ranking can be used to shortlist the set of candidate genes that
needs to be further validated. In addition to the data extracted from biological databases,
GUILDify lets users to input their own set of annotations to be used in the prioritization.
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Systems-level characterization of dysregulation patterns
in cancer
Cancer is a complex, pathway-centric phenotype. Even slightest changes in intercon-
nected pathways can cause abnormal regulation events affecting whole system. Charac-
terization of dysregulation patterns in cancer requires the integration of multiple types of
data including information on gene regulation, signaling and cell metabolism as well as
the cross-talk between them. Systems biology approaches aim to foresee the outcome
of perturbations in regulation patterns by incorporating protein-protein interactions in
addition to proteomic, genomic, metabolic, physiological and environmental informa-
tion defining a dynamic context and possibly suggesting points of action [Pujol et al.,
2010, Fliri et al., 2010]. These approaches can have multiple biological and clinical
applications: first, they may identify disease genes and disease pathways; second, they
can be used to discover new targets and to develop new drugs; and third, some of these
new targets can be used as more accurate cancer biomarkers leading to improved per-
sonalized therapies and treatments [Barabasi et al., 2011].
Future directions
Network-based prioritization offers a great opportunity to rank genes with respect to
their relevance to the phenotype of interest. However, the accuracy of the methods
depends considerably on the seeds (known associations) and the underlying network.
Using only PPI information to describe the network may fail to identify associations
for the genes whose proteins do not interact with other proteins. Therefore, incorporat-
ing gene expression, functional annotations or phenotypic similarity profiles to employ
a network where the links are ”functional associations” rather than solely physical in-
teractions could significantly improve the prioritization accuracy. Several works have
already reported favorable results using functional association networks [Franke et al.,
2006]. It would be very interesting to see how the methods presented here work using
such kind of networks.
Towards a comprehensive understanding of biological pathways underlying dis-
eases, it would be also engaging to use the methods presented here to discover so called
”active subnetworks”, clusters of genes in the PPI network that account for the observed
phenotypic difference. A recent study has employed PageRank with priors to identify
such subnetworks [Nibbe et al., 2010b]. Considering that the methods presented here
outperformed this algorithm, biologically more sound results can be achieved.
Another application area of the methods presented here would be prioritization of
SNP data coming from GWAS. Using network-based prioritization is tempting con-
sidering the collaborative role of genetic variants in diseases. Rare variants that are
frequently skipped during the analysis of GWAS data can be pinpointed using presented
methods albeit some inherent limitations such as most of the SNPs falling under a non-
coding region. In fact, PageRank with priors method has already been applied to this
problem as well [Lee et al., 2011, Akula et al., 2011].
A topic gaining attraction in the research community lately is investigation of path-
ways shared among disease. Identifying the genetic elements common to diseases and
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reusing existing drugs accordingly (drug repurposing) has been central to research ef-
forts recently. These methods can characterize the interconnected pathways implicated
in diseases and possibly suggest points of action to compensate the changes induced by
the disease [Zanzoni et al., 2009].
At last but not least, given that the gene-gene interactions are the key descriptors of
biological function, the network-based prioritization methods can be adopted to predict
genetic interactions. Efforts towards this direction has also been exerted recently, in par-
ticular using Random walk with restart method [Chipman and Singh, 2009] to calculate
the proximity in the network and score interactions in non-human species. However,
in order to predict genetic interactions in human and to take into account the biologi-
cal context that makes genetic interactions plausible, annotations of relevant biological
functions identified in model organisms can be transferred to human and gene pairs pri-







The main contributions of this thesis can be summarized as follows:
• A novel network-based disease-gene prioritization framework, GUILD, has been
implemented and made publicly available. GUILD associates genes with diseases
using the global topology of the network and an initial set of genes known to be
implicated in the disease (seeds).
• The prediction of accuracy of the algorithms in GUILD is evaluated on human
genetic diseases using PPI networks. The results show that proposed algorithms
exploit the global topology of the network better than existing algorithms.
• The genes prioritized by GUILD for a particular disease are more likely to be
implicated in the disease than the rest of the genes encoding the proteins in the
interaction network.
• The outcome of the network-based prioritization depends on the network and
seeds. A combination of these two features, the connectedness of the seeds in
the network, defines the success of the prioritization.
• The perturbations on the input data affect all the prioritization algorithms how-
ever, some of the prioritization algorithms in GUILD are more robust against
perturbations than the others.
• For several diseases, disease-gene annotations are easier to be recovered using
network-based prioritization methods suggesting robustness at pathophenotypic
level. The robustness of disease phenotypes emerging from the underlying bio-
logical system is probably due to i) alternative routes in the interaction network
connecting the seeds and ii) functionally diverse modules in which the seeds are
connected with shorter paths.
• GUILD has been extended as an online and user-friendly tool (GUILDify) where
the genes can be prioritized for their association to any user-provided phenotype.
GUILDify ranks genes in human interactome fetching initial gene-phenotype as-
sociations for a given phenotype from BIANA, a biological data integration plat-
form.
• The current state-of-the-art systems-biology approaches towards delineating dis-
ease mechanisms –particularly in various types of cancer– have been reviewed








BIANA: A software framework for





















Therapeutic benefits of stem cells given their  unrestricted differentiation potential  are out of question. 
Though,  the  mechanism beneath  the  developmental  process  these  stem cells  undertake  is  far  less 
understood. Embryonic stem cell (ESC) fate is shown to be dynamically regulated by transcription factors, 
their  interactions and epigenetic modifiers (mainly miRNAs and methylation events).  Widely accepted 
view on cell  fate  determination suggests  that  state  of  a  cell  is  determined by the interplay of  these 
transcriptional regulation elements yielding in transitions between several coexisting stable states [1].
Core regulatory circuitry mediating ESC self renewal and differentiation has been fairly explained [2] and 
interest  is  recently shifting towards identifying transcription factors  involved in the later stages of  the 
embryonic development [3]. Studies demonstrate that cells at similar differentiation state cluster together 
with respect to their gene expression profiles [4,5]. Furthermore, it has been shown that group of "actively 
communicating" genes (bearing differential expression patterns and whose products interact) has more 
discriminative power in terms distinguishing a certain phenotype or cell type than individual genes alone 
[6,7].  Thus,  combining gene expression data with  transcription factor  interaction data and annotation 
information at the developmental level can provide insights to the key transcription factors mediating cell 
fate.
Associating transcription factors  with  their  role in  cell  lineage requires a well  structured relationships 
hierarchy between the steps of the lineage. Though, the Gene Ontology (GO) [8] is among one of the 
most comprehensive functional annotation source, it does not contain developmental lineage information 
[9] but rather focus on defining biological processes behind the development. On the other hand, the Cell 
Ontology [10] and more recently an anatomy oriented ontology [11] also aim to provide a basic framework 
for cell types but fail to capture the human developmental lineage categorize genes falling under each 
specific category.
Integration of gene expression data over multiple experiments can benefit addressing the cell types or 
developmental stages a gene is expressed in [12,13]. One prominent approach is Bgee database which 
collects information in which organs and at which developmental stages a gene is expressed [12] through 
ontology mapping. Recently, Novershtern et al. [14] identified modules of highly coexpressed genes in 
investigated  roles  of  these  modules  in  hematopoietic  differentiation.  They  showed  that  some of  the 
identified modules are specific to certain lineages and controls changes in differentiation. On the other 
hand, Ravasi et al.  [7] identified modules involved in tissue development and classified the cell  lines 
according to their embryonic origin (endoderm, mesoderm, ectoderm).
Here, we use a large compendium of microarray experiments and develop a bioinformatics method to 
identify gene sets as the mediators of differentiation over human developmental cell lineage. We then 
investigate to which extent these gene sets can be used to distinguish the cell line of given sample.
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Results and Discussion
Human developmental lineage tree
Throughout human development stem cells go through various steps of differentiation yielding in different 
tissues and cell  types.  We built  an ontology containing all  the cell  types we had experimental  gene 
expression data to capture these possible paths of differentiation (Figure 1). This ontology was referred 
as the human lineage tree, since the path from the root to each leaf constituted a possible path that a cell 
can undertake during differentiation. Therefore, the tree described all possible lineages that a cell could 
commit (e.g., from embryonic stem cell to liver cell). The lineage tree covered a diverse set of cell types 
including  both  fully  differentiated  cells  such  as  tissue  specific  smooth  muscle  cells  and  rather  less 
differentiated germ layer cells like ectoderm, mesoderm and endoderm. The expression data containing 
697 samples was laid over the lineage tree (see Methods). Fully undifferentiated cells, that is ESCs, were 
a lot more represented in the gene expression dataset with 425 samples, whereas there was no sample 
from germ layers and there were only a handful of samples for fully differentiated cells. This is because 
controlling  the state  of  the germ layer  cells  is  often not  possible  due to  unavailability  of  biomarkers 
distinguishing these kind of  cell types. Consequently, we did not have gene expression data for some of 
these cell states and we imputed information for these states using their children cell states in the lineage 
tree as a proxy.  
Figure  1. Lineage  tree  for  the  cell  states  in  the  human  cell  differentiation.  Node  size  is  scaled  in 
accordance  to  the  number  of  total  samples.  The  nodes  are  colored  with  respect  to  the  number  of 
microarray samples that belong to those nodes (cell states). 
Expression coherence among arrays
We confirmed the homogeneity of the samples for the ESCs and the three germ layer cells,  namely 
ectoderm, mesoderm, endoderm cells by calculating the sample-wide correlation of the expression of all 
the genes in these samples with each other (Figure 2). The gene expression among the samples of the 
three germ layers was less coherent, due to using the samples of more differentiated tissues to describe 
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these cell states (e.g., using neural stem and brain cells to proxy ectoderm). Furthermore, there were 
groups of ESC samples that were rather correlated with ectoderm, mesoderm and endoderm samples. 
Although these annotations were spurious, they were not removed from the dataset since all of these 
samples were experimentally verified as stem cells (i.e. via checking the existence of various stem cell 
markers).
Figure 2. Correlation matrix for the gene expression samples of ESC and the three germ layer cells.
Gene expression patterns at the top of the lineage tree 
In order to identify the genes mediating the cell fate decisions, we applied a statistical difference-of-mean 
test comparing the samples of one cell  state and all the remaining samples (see Methods). Figure 3 
shows top differentially expressed five genes among the ESC and three germ layer samples. Consistent 
with known stem cell maintenance and commitment mechanisms, POUF51 (a.k.a. OCT4) stood out as an 
important player showing dominantly up-regulation pattern during maintenance (among ESC samples) 
and down-regulation during commitment (among the samples of germ layers). Other known mediators of 
stem cell differentiation such as SOX2 and NANOG were also highly differentially expressed in ESCs 
(see Supplementary Material).
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Figure 3. Top differentially up-regulated genes in ESC and the germ layer cells.
Next, we checked whether there was an enrichment in terms of up-regulated transcription factors in these 
cell  states,  i.e.  if  several  cell  states  were  more  “active”  compared  to  others.  Figure  4   shows  the 
distribution of the number of up-regulated transcription factors as a function of the standard deviation of 
the gene expression distribution within the samples of each cell state. The number of active transcription 
factors were similar in all cell types, though endoderm showed a slightly increased tendency to have more 
up-regulated  transcription  factors.  Nevertheless,  none  of  the  differences  in  number  of  up-regulated 
transcription factors was significant (assessed by a two-sided t-test, alpha value 0.05) suggesting that 
similar number of transcription factors were involved in the cell fate determination at the top of the lineage 
tree.
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Figure 4. Number of up-regulated transcription factors in ESC and the germ layer cells at different 
standard deviation cutoffs of normalized gene expression distribution (z scores). For each sample, the 
gene expression values were standardized using the expression values of each gene in order to have a 
normal-like distribution with mean 0 and standard deviation 1. 
Predicting mediators of cell fate
Differential expression plays an important role in defining the cell state during differentiation. Using gold 
standard  dataset  for  ESC,  and the  germ layers,  we  investigated  the  capability  of  test  of  differential 
expression to distinguish the cell state. Based on the hypothesis that the genes involved in one cell state 
should  be differentially  expressed  compared to  other  states  in  general,  we  compared the  means of 
distribution of gene expression in the samples of one cell state compared to the rest of the samples. The 
prediction performance was assessed as the area under ROC curve (Table 1). Among all the approaches 
evaluated  (see  Methods),  Welch's  test  with  versus  rest  grouping  strategy  and  considering  only  up-
regulated transcription factors achieved the best prediction performance. That is, a gene was more likely 
to be involved in the differentiation of a cell state if it was a transcription factor and its expression in that  
cell  state was significantly higher than its expression in the rest of the cell  types using Welch’s test. 
Moreover, we are currently working on  i) improving predictions using regulatory relationships between 
genes  (e.g.,  gene  co-expression)  and  ii) incorporating  topology-based  scores  coming  from  the 
neighborhood  of  the  genes  in  the  protein-protein  interaction  network  in  addition  to  differential  gene 
expression. 
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Table 1. Prediction accuracy of test of differential expression for embryonic stem, ectoderm, mesoderm 
and endoderm cell states.
Cell state Area under ROC (%)




Predicting cell line of origin for the validation samples
The genes involved in the differentiation of cell types at the top of the lineage tree were predicted with a 
reasonable accuracy using differential expression. We extended this rationale to annotate the cell type of 
a given sample. Accordingly, the cell state of a given sample was predicted by comparing the expression 
of genes in the sample with the expression of genes in each cell state in the lineage tree (see Methods). 
First, we applied a ten-fold cross-validation procedure to find the optimum number of differentially up-
regulated genes that discriminate the cell states. The average number of correctly classified arrays using 
one array from each cell state (24 in total) at three different runs of cross-validation is given in Table 2. 
Next, we predicted the cell types of 16 additional arrays provided in the validation set (two samples in the 
validation set were not considered since it was not possible to map these samples to any of the cell states 
in the lineage tree) using most up-regulated 31 genes. This yielded in a relatively low precision of 3 out of 
16 samples. However, considering that there were 70 possible cell states in the data set, this prediction 
performance is considerably better than random. We have also tested using gene-sets such as genes 
belonging to GO terms or complexes in CORUM database for their capacity to distinguish the cell state. 
Using the genes associated with certain GO terms improved the number of correctly predicted samples 
substantially for various GO terms (see Supplementary Material).
Table 2. 10-fold cross validation using up-regulated k transcription factors.
Cross validation run 
id 





Human developmental lineage tree
Possible  paths  of  human  stem  cell  differentiation  have  been  captured  as  an  ontology  we  curated 
combining cell fate maps from Gilbert (2000) and Galvao et al. (2010). In case of inconsistency or lack of 
information in these two sources, we looked for further evidence from literature. We provided the ontology 
in Open Biological and Biomedical Ontology (OBO) format (see Supplementary Material).  The ontology 
contained 70 terms, each of which corresponded to a distinct cell state. These terms were connected by 
“lineage of” relationships. 
Gene expression and transcription factor data  
The  gene  expression  data  was kindly  provided  by  Jeanne Loring's  Regenerative  Medicine  group  in 
Scripps Institute through a collaboration. They have screened expression of genes on 709 samples from 
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human corresponding to 66 different cell types at various levels of human development using Illimuna 
BeadArray platform (31007 probes covering 23659 genes). The samples and the cell types they were 
assigned is given in the Supplementary Material. They  provided bead-level expression information for the 
probes that passed the detection p-value cutoff (less than or equal to 0.05). This data was then quantile 
normalized and converted to log-ratios. Among 709 samples, 12 samples were tumor-like samples and 
thus discarded during the analyzes. In addition to these samples, a validation data set consisting of 18 
samples  created  with  using  another  Illimuna-based  platform  were  provided  independently  (see 
Supplementary Material). These latter samples contained 28113 probes covering 17858 genes.
For the cell states for which no experimental data available, we used the samples falling under these 
states  to  describe  the  gene  expression  patterns  in  these  cell  states.  For  each  of  such  states,  we 
considered the expression data assigned to their children states in the lineage tree as a proxy.
During analyzes, we used the list of human transcription factors provided by Ravasi et al. [Ravasi10]. We 
also  added  DNMT3B  and  FGF5  to  this  dataset  for  which  the  transcriptional  activity  was  already 
demonstrated. The complete list  of transcription factors consisted of 1723 genes (see  Supplementary 
Material).
Determining differential gene expression patterns
We used several statistical tests to compare gene expression levels of each gene under various parts of 
the created lineage tree based on the hypothesis that genes deriving a cell type to another should bear 
expression patterns characteristic to these cell types. These statistical tests include Kolmogorov-Smirnov 
divergence, Welch's test  (a modification of t-test  accounting for distributions with unequal variances), 
Jensen-Shannon divergence as well as simply amount of absolute expression and amount of change in 
the mean expression level (referred as abundance test and abundance difference test respectively). We 
have also checked 3 different strategies to group the samples over the tree in order to identify the most 
plausible way of capturing the differentiation process through the statistical test where the first  group 
being  the  samples  corresponding  to  the  cell  type  for  which  a  gene  in  concern  was  mediating 
differentiation and the second being other cell types assumed to be involved in the determination of the 
cell  fate  for  the  cell  type  in  concern.  The  first  strategy,  versus  parent  and  siblings compared  the 
expression  of  a  gene  g given  in  a  cell  type  c,  with  respect  to  expression  of  g in  the  cell  types 
corresponding to c's parent and sibling nodes in the lineage tree. Similarly, the second strategy, versus 
siblings, compared the expression of g in c with respect to siblings of c. The final strategy,  versus rest, 
compared the expression of g in c with the expression of g in the rest of the samples.
We assessed the prediction performance of these methods on a small set of genes known to be involved 
in the differentiation of embryonic stem and the germ layer cells. This gold standard dataset was mainly 
curated from the literature (Takahashi et al., 2006; Jaenisch and Young, 2008; Lemischka et al., 2009). 
The  genes  included  from literature  were  further  curated  by  experts  by  the  group  that  provided  the 
expression data. All the genes in the gold standard that were annotated with a cell type other than the cell  
type in concern were considered as negative cases (genes that were not involved in that cell type). The 
prediction performance was evaluated using area under ROC curve (AUC).
Predicting mediators of cell fate
A centroid-based clustering approach was taken to classify a given sample based on existing samples. 
Instead of  using  all  possible  genes,  we  compared only  the expression of  the most  differentially  up-
regulated k genes in each cell  state with the expression of these genes in the sample of interest.  A 
centroid vector for each state was generated using average expression of top differentially up-regulated k 
genes in all samples for that state.  For each state, the similarity between the centroid vector and the 
expression of the same genes included in the centroid vector for the given sample was calculated using a 
correlation-based  distance  metric.  The  array  was  then  predicted  as  the  cell  state  with  the  closest 
distance. To find the optimum number of most differentially up-regulated genes, k, we employed a ten-fold 
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cross-validation procedure and split the samples in the gene expression dataset for which we had more 
than 10 samples into ten groups. There were 24 cell states in the dataset for which there were more than 
10 samples. A cross validation group was created using randomly selecting one sample among all of the 
samples  associated  with  each  of  these  states  and  this  procedure  was  repeated  10  times  (without 
replacing the selected samples). We used 9 of these groups to identify differentially expressed genes for 
each cell state and then predicted the cell state of the left-out samples (10th group) for varying values of k 
in the range of 1 to 80. In addition to using k up-regulated genes, we used the genes involved in known 
complexes in CORUM database as well as genes associated with GO terms. In this gene-set oriented 
approach, the average expression of the genes of the complex/GO term in the samples of each cell state 
was compared with the expression of the same genes in the sample. 
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